<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1384" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1384/" /><meta name="ncbi_pagename" content="FMR1 Disorders - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>FMR1 Disorders - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="FMR1 Disorders" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2019/11/21" /><meta name="citation_author" content="Jessica Ezzell Hunter" /><meta name="citation_author" content="Elizabeth Berry-Kravis" /><meta name="citation_author" content="Heather Hipp" /><meta name="citation_author" content="Peter K Todd" /><meta name="citation_pmid" content="20301558" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1384/" /><meta name="citation_keywords" content="Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS)" /><meta name="citation_keywords" content="Fragile X Syndrome (FXS)" /><meta name="citation_keywords" content="FMR1 Primary Ovarian Insufficiency (FXPOI)" /><meta name="citation_keywords" content="Synaptic functional regulator FMR1" /><meta name="citation_keywords" content="FMR1" /><meta name="citation_keywords" content="FMR1 Disorders" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="FMR1 Disorders" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Jessica Ezzell Hunter" /><meta name="DC.Contributor" content="Elizabeth Berry-Kravis" /><meta name="DC.Contributor" content="Heather Hipp" /><meta name="DC.Contributor" content="Peter K Todd" /><meta name="DC.Date" content="2019/11/21" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1384/" /><meta name="description" content="FMR1 disorders include fragile X syndrome (FXS), fragile X-associated tremor/ataxia syndrome (FXTAS), and fragile X-associated primary ovarian insufficiency (FXPOI)." /><meta name="og:title" content="FMR1 Disorders" /><meta name="og:type" content="book" /><meta name="og:description" content="FMR1 disorders include fragile X syndrome (FXS), fragile X-associated tremor/ataxia syndrome (FXTAS), and fragile X-associated primary ovarian insufficiency (FXPOI)." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1384/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/fragilex/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1384/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE890093E04063E10000000007600325.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1384_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1384_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/flnb-dis/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/foxp2-sl-dis/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1384_"><span class="title" itemprop="name"><i>FMR1</i> Disorders</span></h1><p class="contrib-group"><span itemprop="author">Jessica Ezzell Hunter</span>, PhD, <span itemprop="author">Elizabeth Berry-Kravis</span>, MD, PhD, <span itemprop="author">Heather Hipp</span>, MD, and <span itemprop="author">Peter K Todd</span>, MD, PhD.</p><a data-jig="ncbitoggler" href="#__NBK1384_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1384_ai__"><div class="contrib half_rhythm"><span itemprop="author">Jessica Ezzell Hunter</span>, PhD<div class="affiliation small">Center for Health Research<br />Kaiser Permanente Northwest<br />Portland, Oregon<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.rhcpk@retnuh.e.acissej" class="oemail">gro.rhcpk@retnuh.e.acissej</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Elizabeth Berry-Kravis</span>, MD, PhD<div class="affiliation small">Departments of Pediatrics, Neurological Sciences, and Biochemistry<br />Rush University Medical Center<br />Chicago, Illinois<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.hsur@sivark-yrreb_htebazile" class="oemail">ude.hsur@sivark-yrreb_htebazile</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Heather Hipp</span>, MD<div class="affiliation small">Division of Reproductive Endocrinology and Infertility<br />Emory University School of Medicine<br />Atlanta, Georgia<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.yrome@ppihh" class="oemail">ude.yrome@ppihh</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Peter K Todd</span>, MD, PhD<div class="affiliation small">Department of Neurology<br />University of Michigan Medical School<br />Ann Arbor, Michigan<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.hcimu.dem@dotretep" class="oemail">ude.hcimu.dem@dotretep</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">June 16, 1998</span>; Last Update: <span itemprop="dateModified">November 21, 2019</span>.</p><p><em>Estimated reading time: 53 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="fragilex.Summary" itemprop="description"><h2 id="_fragilex_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p><i>FMR1</i> disorders include fragile X syndrome (FXS), fragile X-associated tremor/ataxia syndrome (FXTAS), and fragile X-associated primary ovarian insufficiency (FXPOI).</p><ul><li class="half_rhythm"><div>Fragile X syndrome occurs in individuals with an <i>FMR1</i> full mutation or other <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> variant and is nearly always characterized in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males by developmental delay and intellectual disability along with a variety of behavioral issues. Autism spectrum disorder is present in 50%-70% of individuals with FXS. Affected males may have characteristic craniofacial features (which become more obvious with age) and medical problems including hypotonia, gastroesophageal reflux, strabismus, seizures, sleep disorders, joint laxity, <i>pes planus</i>, scoliosis, and recurrent otitis media. Adults may have mitral valve prolapse or aortic root dilatation. The physical and behavioral features seen in males with FXS have been reported in females <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for the <i>FMR1</i> full mutation, but with lower frequency and milder involvement.</div></li><li class="half_rhythm"><div>FXTAS occurs in individuals who have an <i>FMR1</i> <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> and is characterized by late-onset, progressive cerebellar ataxia and intention tremor followed by cognitive impairment. Psychiatric disorders are common. Age of onset is typically between 60 and 65 years and is more common among males who are <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> for the premutation (40%) than among females who are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for the premutation (16%-20%).</div></li><li class="half_rhythm"><div>FXPOI, defined as hypergonadotropic hypogonadism before age 40 years, has been observed in 20% of women who carry a <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> compared to 1% in the general population.</div></li></ul></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of an <i>FMR1</i> disorder is established through the use of specialized <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> to detect CGG <a class="def" href="/books/n/gene/glossary/def-item/trinucleotide-repeat/">trinucleotide repeat</a> expansion in the 5' UTR of <i>FMR1</i> with abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/methylation/">methylation</a> for most alleles with &#x0003e;200 repeats. Typically, a definite diagnosis of FXS requires the presence of a full-mutation repeat size (&#x0003e;200 CGG repeats) while the diagnosis of FXTAS or FXPOI is associated with a <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a>-sized repeat (55-200 CGG repeats). It should be noted that typical multigene panels and comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing (<a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> or <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a>) are useful only when no CGG repeat expansion is detected but FXS is still suspected.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i></p><ul><li class="half_rhythm"><div>Fragile X syndrome. Supportive and symptom-based therapy for children and adults typically consisting of a dual approach of psychopharmacologic treatment of symptoms as needed in conjunction with therapeutic services, such as behavioral intervention, speech and language therapy, occupational therapy, and individualized educational support; routine treatment of medical problems.</div></li><li class="half_rhythm"><div>FXTAS. Symptomatic and supportive and should be tailored to the individual.</div></li><li class="half_rhythm"><div>FXPOI. Gynecologic or reproductive endocrinologic evaluation can provide appropriate treatment and counseling for reproductive considerations and hormone replacement.</div></li></ul><p><i>Agents/circumstances to avoid:</i></p><ul><li class="half_rhythm"><div>FXTAS. Typical and atypical antipsychotics with significant anti-dopaminergic effects and metoclopramide, which can exacerbate parkinsonism; anticholinergic agents, which can exacerbate cognitive complaints; excessive alcohol, which can enhance cerebellar dysfunction and postural instability; agents with known cerebellar toxicity or side effects.</div></li><li class="half_rhythm"><div>FXPOI. Tobacco use as this decreases ovarian reserve and the age of onset of FXPOI.</div></li></ul></div><div><h4 class="inline">Genetic counseling.</h4><p><i>FMR1</i> disorders are inherited in an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> manner:</p><ul><li class="half_rhythm"><div>All mothers of individuals with an <i>FMR1</i> full mutation (expansion &#x0003e;200 CGG trinucleotide repeats and abnormal <a class="def" href="/books/n/gene/glossary/def-item/methylation/">methylation</a>) are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for an <i>FMR1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. Mothers and their female relatives who are heterozygous for a <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> are at increased risk for FXTAS, FXPOI, and fragile X-associated neuropsychiatric disorders (FXAND); those with a full mutation may have findings of fragile X syndrome. All are at increased risk of having offspring with fragile X syndrome, FXTAS, FXPOI, or FXAND.</div></li><li class="half_rhythm"><div>Males with premutations are at increased risk for FXTAS. Males with FXTAS will transmit their <i>FMR1</i> <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> expansion to all of their daughters, who will be <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a premutation and at increased risk for FXTAS, FXPOI, and FXAND. Males with FXTAS do not transmit their <i>FMR1</i> premutation to sons.</div></li></ul><p>Prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-testing/">preimplantation genetic testing</a> are possible once an expanded (or altered) <i>FMR1</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> has been identified in a family member.</p></div></div><div id="fragilex.GeneReview_Scope"><h2 id="_fragilex_GeneReview_Scope_"><i>GeneReview</i> Scope</h2><div id="fragilex.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1384/table/fragilex.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fragilex.Tc_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_fragilex.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>FMR1</i> Disorders: Included Phenotypes&#x000a0;<sup>1</sup></th></tr></thead><tbody><tr><td headers="hd_h_fragilex.Tc_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Fragile X syndrome (FXS)</div></li><li class="half_rhythm"><div>Fragile X-associated tremor/ataxia syndrome (FXTAS)</div></li><li class="half_rhythm"><div><i>FMR1</i> primary ovarian insufficiency (FXPOI)</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">For synonyms and outdated names see <a href="#fragilex.Nomenclature">Nomenclature</a>.</p></div></dd><dt>1. </dt><dd><div id="fragilex.TF.c.1"><p class="no_margin">For other genetic causes of these phenotypes see <a href="#fragilex.Differential_Diagnosis">Differential Diagnosis</a>.</p></div></dd></dl></div></div></div></div><div id="fragilex.Diagnosis"><h2 id="_fragilex_Diagnosis_">Diagnosis</h2><div id="fragilex.Suggestive_Findings"><h3>Suggestive Findings</h3><p><i>FMR1</i> disorders <b>should be considered</b> in individuals with the following clinical and associated findings.</p><p><b>Fragile X syndrome (FXS)</b></p><ul><li class="half_rhythm"><div>Males and females with intellectual disability or developmental delay of unknown cause</div></li><li class="half_rhythm"><div>Males with unexplained autism spectrum disorder and females with unexplained autism spectrum disorder and the presence of an additional indicator: <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> compatible with FXS; family history of <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> neurodevelopmental disorders; or premature ovarian failure, ataxia, or tremors in close relatives</div></li></ul><p><b>Fragile X-associated tremor/ataxia syndrome (FXTAS)</b></p><ul><li class="half_rhythm"><div>Males and females who are experiencing late-onset intention tremor and cerebellar ataxia of unknown cause. Men and women with dementia may also be considered, if ataxia, parkinsonism, or tremor are also present.</div></li><li class="half_rhythm"><div>Males and females with multiple system atrophy, cerebellar subtype (especially if a prolonged course)</div></li></ul><p><b>Fragile X-associated primary ovarian insufficiency (FXPOI).</b> Females with unexplained primary ovarian insufficiency or failure (hypergonadotropic hypogonadism) before age 40 years</p></div><div id="fragilex.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of an <i>FMR1</i> disorder <b>is established</b> through the use of specialized <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>. It should be noted that typical multigene panels and comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing (<a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> or <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a>) are useful only when no CGG repeat expansion is detected but FXS is still suspected.</p><p><i>FMR1</i> related disorders are caused by CGG <a class="def" href="/books/n/gene/glossary/def-item/trinucleotide-repeat/">trinucleotide repeat</a> expansion in the 5' UTR of <i>FMR1</i> with abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/methylation/">methylation</a> for most alleles with more than 200 repeats. Typically, a definite diagnosis of FXS requires the presence of a full-mutation repeat size (&#x0003e;200 CGG repeats) while the diagnosis of FXTAS or FXPOI is associated with a <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a>-sized repeat (55-200 CGG repeats).</p><div id="fragilex.Allele_Size"><h4>Allele Size</h4><p><i>FMR1</i> alleles are categorized according to the number of 5' UTR CGG trinucleotide repeats and the <a class="def" href="/books/n/gene/glossary/def-item/methylation/">methylation</a> status of the repeat region. However, the distinction between <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> categories is not absolute and must be made by considering both family history and repeat instability. The size boundary between intermediate and <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> categories listed below is not precise and caution is advised. See <a class="figpopup" href="/books/NBK1384/table/fragilex.T.types_of_fmr1_repeat_expansio/?report=objectonly" target="object" rid-figpopup="figfragilexTtypesoffmr1repeatexpansio" rid-ob="figobfragilexTtypesoffmr1repeatexpansio">Table 3</a> for a summary of the types of <i>FMR1</i> alleles and clinical status of individuals with expanded alleles.</p><p>Stability of alleles of fewer than 90 repeats is heavily influenced by the number of AGG interspersions within the CGG repeat sequence, both with respect to risk for size change in intermediate alleles and small premutations and expansion to a full mutation in <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> alleles larger than about 60 repeats [<a class="bk_pop" href="#fragilex.REF.nolin.2013.771">Nolin et al 2013</a>, <a class="bk_pop" href="#fragilex.REF.nolin.2019.1148">Nolin et al 2019</a>]. This information should be utilized when appropriate for counseling families about expansion risk.</p><p>See <a href="#fragilex.Anticipation">Anticipation</a> for detailed information on factors such as AGGs that influence <i>FMR1</i> CGG repeat stability.</p><p><b>Normal alleles.</b> Approximately 5-44 repeats</p><ul><li class="half_rhythm"><div>Alleles of this size have little meiotic or mitotic instability and are typically transmitted without any increase or decrease in repeat number. However, some instability in normal repeats has been reported, with alleles that contain no AGG interspersions having a greater likelihood to be unstable [<a class="bk_pop" href="#fragilex.REF.nolin.2019.1148">Nolin et al 2019</a>].</div></li><li class="half_rhythm"><div>The population distribution of <i>FMR1</i> repeat alleles shows the highest percentage of individuals with approximately 29-31 repeats; smaller but significant percentages cluster around 20 and 40 repeats.</div></li></ul><p><b>Intermediate alleles</b> (also termed "gray zone" or "borderline"). Approximately 45-54 repeats</p><ul><li class="half_rhythm"><div class="half_rhythm">Intermediate alleles do not cause FXS. However, about 14% of intermediate alleles are unstable and may expand into the <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> range when transmitted by the mother [<a class="bk_pop" href="#fragilex.REF.nolin.2011.925">Nolin et al 2011</a>]. They are not known to expand to full mutations; therefore, offspring are not at increased risk for FXS.</div></li><li class="half_rhythm"><div class="half_rhythm">Historically, the largest repeat included in the intermediate range has been 54; the use of 54 as the upper limit for normal alleles is a conservative estimate reflecting observations that transmission of alleles with 54 or fewer repeats from mothers to their offspring has not resulted in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual to date. The conservative nature of the estimate also reflects potential imprecision (usually stated as &#x000b1;2-3 repeats) in laboratory measurement of repeat number during diagnostic testing; however, to date no transmission of alleles with 55 or fewer repeats is known to have resulted in an affected individual [<a class="bk_pop" href="#fragilex.REF.nolin.2015.358">Nolin et al 2015</a>, <a class="bk_pop" href="#fragilex.REF.nolin.2019.1148">Nolin et al 2019</a>].</div><div class="half_rhythm">Note: Clinical laboratories performing <i>FMR1</i> analysis typically state their estimated precision range when measuring intermediate alleles and usually report their estimates as &#x000b1;2-3 repeats. Thus, it may be prudent to consider reported test results with 55 repeats as potential premutations. If the repeat precision estimate is not on the laboratory report, the laboratory should be contacted in order to determine if a result should be considered as a potential <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a>.</div></li></ul><p><b>Premutation alleles.</b> Approximately 55-200 repeats</p><ul><li class="half_rhythm"><div class="half_rhythm">Alleles of this size are not associated with FXS but do convey increased risk for FXTAS and FXPOI (<a class="figpopup" href="/books/NBK1384/table/fragilex.T.types_of_fmr1_repeat_expansio/?report=objectonly" target="object" rid-figpopup="figfragilexTtypesoffmr1repeatexpansio" rid-ob="figobfragilexTtypesoffmr1repeatexpansio">Table 3</a>). Because of potential repeat instability upon transmission of <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> alleles, women with alleles in this range are considered to be at risk of having children with FXS, although this risk is heavily dependent on the number of AGG interspersions for small premutation alleles [<a class="bk_pop" href="#fragilex.REF.nolin.2013.771">Nolin et al 2013</a>, <a class="bk_pop" href="#fragilex.REF.nolin.2019.1148">Nolin et al 2019</a>].</div><div class="half_rhythm">Note: The upper limit of the <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> range is sometimes noted as approximately 230. Both numbers (200 and 230) are estimates derived from <a class="def" href="/books/n/gene/glossary/def-item/southern-blot/">Southern blot</a> analysis, in which repeat size can only be roughly estimated.</div></li></ul><p><b>Full-mutation alleles.</b> More than 200 CGG repeats, with several hundred to several thousand repeats being typical and, in most cases, associated with aberrant hypermethylation of the <i>FMR1</i> promoter. Almost always, extensive somatic variation of repeat number is observed in a peripheral blood specimen of an individual with a full mutation. As a result, clinical laboratories may report this somatic variation as a range of several hundred repeats.</p></div></div><div id="fragilex.Clinical_Criteria"><h3>Clinical Criteria</h3><p>The clinical criteria for diagnosis of <a href="#fragilex.FXTAS">FXTAS</a> or <a href="#fragilex.FXPOI">FXPOI</a> in individuals with a <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> are as follows.</p><div id="fragilex.FXTAS"><h4>FXTAS</h4><p>Three levels are used to indicate the confidence of a diagnosis of FXTAS in individuals with an <i>FMR1</i> <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> based on symptom manifestation at the time of the evaluation [<a class="bk_pop" href="#fragilex.REF.jacquemont.2003.869">Jacquemont et al 2003</a>, <a class="bk_pop" href="#fragilex.REF.berrykravis.2007.2018">Berry-Kravis et al 2007</a>, <a class="bk_pop" href="#fragilex.REF.hagerman.2016.403">Hagerman &#x00026; Hagerman 2016</a>, National Fragile X Foundation FXTAS <a href="https://fragilex.org/fxtas-consensus-document/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Guideline</a>]. The three diagnostic categories:</p><ul><li class="half_rhythm"><div><b>Definite.</b> Presence of one major radiologic sign plus one major clinical sign, or presence of FXTAS inclusions (characteristic ubiquitin-positive intranuclear inclusions within the nuclei of neurons and astrocytes)</div></li><li class="half_rhythm"><div><b>Probable.</b> Presence of either one major radiologic sign plus one minor clinical sign, or two major clinical signs</div></li><li class="half_rhythm"><div><b>Possible.</b> Presence of one minor radiologic sign plus one major clinical sign</div></li></ul><p><b>Radiologic signs</b></p><ul><li class="half_rhythm"><div><b>Major.</b> MRI white matter lesions in middle cerebellar peduncles (MCP sign)</div></li><li class="half_rhythm"><div><b>Minor</b></div><ul><li class="half_rhythm"><div>MRI white matter lesions in cerebral white matter</div></li><li class="half_rhythm"><div>Moderate-to-severe generalized brain atrophy</div></li><li class="half_rhythm"><div>MRI white matter lesions in the splenium of the corpus callosum</div></li></ul></li></ul><p><b>Clinical signs</b></p><ul><li class="half_rhythm"><div><b>Major</b></div><ul><li class="half_rhythm"><div>Intention tremor</div></li><li class="half_rhythm"><div>Cerebellar gait ataxia</div></li></ul></li><li class="half_rhythm"><div><b>Minor</b></div><ul><li class="half_rhythm"><div>Parkinsonism</div></li><li class="half_rhythm"><div>Moderate-to-severe short-term memory deficiency</div></li><li class="half_rhythm"><div>Executive function deficit</div></li><li class="half_rhythm"><div>Neuropathy in lower extremities</div></li></ul></li></ul><p><b>Neuropathologic signs.</b> A major criterion is FXTAS intranuclear eosinophilic inclusions that are ubiquitin positive.</p></div><div id="fragilex.FXPOI"><h4>FXPOI</h4><p>Diagnostic criteria are based on hypergonadotropic hypogonadism in women younger than age 40 who carry a <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>. POI is diagnosed when a woman has (1) experienced four to six months of amenorrhea (absent menses) and (2) has two serum menopausal level FSH values obtained at least one month apart [<a class="bk_pop" href="#fragilex.REF.nelson.2009.606">Nelson 2009</a>, <a class="bk_pop" href="#fragilex.REF.fink.2018.529">Fink et al 2018</a>].</p><p>See <a href="#fragilex.Published_Guidelines__Consensus">Published Guidelines / Consensus Statements</a>.</p></div></div><div id="fragilex.Targeted_Analysis_for_Pathogeni"><h3>Targeted Analysis for Pathogenic Variants</h3><p><b>Polymerase chain reaction (<a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a>)</b> is used to size the CGG <a class="def" href="/books/n/gene/glossary/def-item/trinucleotide-repeat/">trinucleotide repeat</a> region of <i>FMR1</i> with high <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a>. Although early PCR techniques for <i>FMR1</i>-specific PCR were less sensitive to larger premutations and failed to amplify full mutations, PCR techniques now exist to identify virtually all sizes of <i>FMR1</i> expansion mutations.</p><p><b>Repeat-primed <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a></b> allows detection and location of AGG interspersions.</p><p><b><a class="def" href="/books/n/gene/glossary/def-item/southern-blot/">Southern blot</a> analysis</b> detects all <i>FMR1</i> alleles including normal, larger-sized premutations, and full mutations and in addition determines <a class="def" href="/books/n/gene/glossary/def-item/methylation/">methylation</a> status of the <i>FMR1</i> <a class="def" href="/books/n/gene/glossary/def-item/promoter-region/">promoter region</a>. Southern blot may not resolve intermediate alleles well. Abnormal hypermethylation of <i>FMR1</i> is the cause of transcriptional silencing and is critical to assess for full-mutation alleles.</p><p>Note: <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> with newer and more sensitive assays is now adequate for diagnosis and size determination for the <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a>, as well as for identification of the full mutation. <a class="def" href="/books/n/gene/glossary/def-item/southern-blot/">Southern blot</a> is currently only used to determine the <a class="def" href="/books/n/gene/glossary/def-item/methylation/">methylation</a> status for the full mutation and the X-inactivation ratio for females with a premutation or full mutation. As PCR methods for determining methylation gain acceptance in diagnostic testing, the need for Southern blot analysis for determination of methylation of the full mutation and activation ratios of women may decrease [<a class="bk_pop" href="#fragilex.REF.chen.2010.589">Chen et al 2010</a>, <a class="bk_pop" href="#fragilex.REF.chen.2011.528">Chen et al 2011</a>, <a class="bk_pop" href="#fragilex.REF.nahhas.2012.187">Nahhas et al 2012</a>, <a class="bk_pop" href="#fragilex.REF.orpana.2012.2081">Orpana et al 2012</a>, <a class="bk_pop" href="#fragilex.REF.hadd.2016.130">Hadd et al 2016</a>, <a class="bk_pop" href="#fragilex.REF.hayward.2016.762">Hayward et al 2016</a>, <a class="bk_pop" href="#fragilex.REF.hayward.2017.1313">Hayward et al 2017</a>].</p><p><b>Methylation status</b> of a full mutation or activation ratio in female heterozygotes can be assessed by <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a>-based methods independent of measuring the number of CGG repeats [<a class="bk_pop" href="#fragilex.REF.grasso.2014.23">Grasso et al 2014</a>].</p></div><div id="fragilex.Additional_Testing"><h3>Additional Testing</h3><p>Fewer than 1% of individuals with FXS have a sequence variant, a partial <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>, or a full deletion of <i>FMR1</i> (reviewed in <a class="bk_pop" href="#fragilex.REF.sitzmann.2018.11">Sitzmann et al [2018]</a>).</p><p>When no CGG repeat expansion is detected but FXS is still suspected, the options are either a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> or <b>comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>FMR1</i> and other genes of interest (see <a href="#fragilex.Differential_Diagnosis">Differential Diagnosis</a>) is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests. For this disorder a multigene panel that also includes deletion/duplication analysis is recommended (see <a class="figpopup" href="/books/NBK1384/table/fragilex.T.molecular_genetic_testing_use/?report=objectonly" target="object" rid-figpopup="figfragilexTmoleculargenetictestinguse" rid-ob="figobfragilexTmoleculargenetictestinguse">Table 1</a>).</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> involves either <b><a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a></b> or <b><a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a></b>. If exome sequencing is not diagnostic, <a class="def" href="/books/n/gene/glossary/def-item/exome-array/">exome array</a> (when clinically available) needs be considered to detect (multi)<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications that cannot be detected by exome sequencing.</div><div class="half_rhythm">For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</div></li></ul><div id="fragilex.T.molecular_genetic_testing_use" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in <i>FMR1</i> Disorders</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1384/table/fragilex.T.molecular_genetic_testing_use/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fragilex.T.molecular_genetic_testing_use_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_fragilex.T.molecular_genetic_testing_use_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_fragilex.T.molecular_genetic_testing_use_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_fragilex.T.molecular_genetic_testing_use_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Pathogenic Variants Detected&#x000a0;<sup>2</sup></th><th id="hd_h_fragilex.T.molecular_genetic_testing_use_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variant Detection Frequency by Method&#x000a0;<sup>3</sup></th></tr></thead><tbody><tr><td headers="hd_h_fragilex.T.molecular_genetic_testing_use_1_1_1_1" rowspan="5" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>FMR1</i></td><td headers="hd_h_fragilex.T.molecular_genetic_testing_use_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">Targeted analysis for pathogenic variants</td><td headers="hd_h_fragilex.T.molecular_genetic_testing_use_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b><a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a>.</b> CGG expansion in <i>FMR1</i>&#x000a0;<sup>4,&#x000a0;5</sup></td><td headers="hd_h_fragilex.T.molecular_genetic_testing_use_1_1_1_4" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;99%</td></tr><tr><td headers="hd_h_fragilex.T.molecular_genetic_testing_use_1_1_1_3" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;"><b><a class="def" href="/books/n/gene/glossary/def-item/southern-blot/">Southern blot</a>.</b> CGG expansion in <i>FMR1</i> (all repeat ranges); <a class="def" href="/books/n/gene/glossary/def-item/methylation/">methylation</a> status for full-mutation alleles and to determine X-inactivation ratio in women&#x000a0;<sup>4,&#x000a0;6</sup></td></tr><tr><td headers="hd_h_fragilex.T.molecular_genetic_testing_use_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Methylation analysis</td><td headers="hd_h_fragilex.T.molecular_genetic_testing_use_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Methylation of <i>FMR1</i> <a class="def" href="/books/n/gene/glossary/def-item/promoter-region/">promoter region</a>&#x000a0;<sup>7</sup></td><td headers="hd_h_fragilex.T.molecular_genetic_testing_use_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100% of alleles with this modification</td></tr><tr><td headers="hd_h_fragilex.T.molecular_genetic_testing_use_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Deletion/<a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> analysis&#x000a0;<sup>8</sup></td><td headers="hd_h_fragilex.T.molecular_genetic_testing_use_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Large (partial- or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>) <i>FMR1</i> deletions/duplications</td><td headers="hd_h_fragilex.T.molecular_genetic_testing_use_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;1%</td></tr><tr><td headers="hd_h_fragilex.T.molecular_genetic_testing_use_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>9</sup></td><td headers="hd_h_fragilex.T.molecular_genetic_testing_use_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>FMR1</i> sequence variants&#x000a0;<sup>4,&#x000a0;5</sup></td><td headers="hd_h_fragilex.T.molecular_genetic_testing_use_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;1%</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="fragilex.TF.1.1"><p class="no_margin">See <a href="/books/NBK1384/#fragilex.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="fragilex.TF.1.2"><p class="no_margin">See <a href="#fragilex.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="fragilex.TF.1.3"><p class="no_margin">The ability of the test method used to detect a variant that is present in the indicated <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a></p></div></dd><dt>4. </dt><dd><div id="fragilex.TF.1.4"><p class="no_margin">Sequence analysis, <a class="def" href="/books/n/gene/glossary/def-item/targeted-analysis-for-pathogenic-variants/">targeted analysis for pathogenic variants</a> using <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a>, and in some instances <a class="def" href="/books/n/gene/glossary/def-item/southern-blot/">Southern blot</a> analysis cannot detect an <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> on the X <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> in <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females.</p></div></dd><dt>5. </dt><dd><div id="fragilex.TF.1.5"><p class="no_margin">Lack of amplification by <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> prior to <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> can suggest a putative (multi)<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> on the X <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males; confirmation requires additional testing by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>.</p></div></dd><dt>6. </dt><dd><div id="fragilex.TF.1.6"><p class="no_margin">As newer and more sensitive <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> methods gain acceptance in diagnostic testing, the need for <a class="def" href="/books/n/gene/glossary/def-item/southern-blot/">Southern blot</a> analysis may decrease [<a class="bk_pop" href="#fragilex.REF.chen.2010.589">Chen et al 2010</a>, <a class="bk_pop" href="#fragilex.REF.chen.2011.528">Chen et al 2011</a>, <a class="bk_pop" href="#fragilex.REF.orpana.2012.2081">Orpana et al 2012</a>, <a class="bk_pop" href="#fragilex.REF.nahhas.2012.187">Nahhas et al 2012</a>, <a class="bk_pop" href="#fragilex.REF.hayward.2016.762">Hayward et al 2016</a>, <a class="bk_pop" href="#fragilex.REF.hayward.2017.1313">Hayward et al 2017</a>].</p></div></dd><dt>7. </dt><dd><div id="fragilex.TF.1.7"><p class="no_margin">Methylation status can be determined by either <a class="def" href="/books/n/gene/glossary/def-item/southern-blot/">Southern blot</a> or <a class="def" href="/books/n/gene/glossary/def-item/methylation/">methylation</a>-specific <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a>; the latter may offer a more rapid test turnaround time [<a class="bk_pop" href="#fragilex.REF.hayward.2017.1313">Hayward et al 2017</a>].</p></div></dd><dt>8. </dt><dd><div id="fragilex.TF.1.8"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>9. </dt><dd><div id="fragilex.TF.1.9"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd></dl></div></div></div><p>Note: (1) If the clinical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> is strongly suggestive of FXS and <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of DNA extracted from leukocytes is normal, molecular genetic testing of a second tissue type (e.g., skin fibroblasts) should be considered as <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a> has been reported [<a class="bk_pop" href="#fragilex.REF.mackenzie.2006.39">MacKenzie et al 2006</a>]. (2) For intermediate and small <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> alleles in <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females, AGG trinucleotide <a class="def" href="/books/n/gene/glossary/def-item/genotyping/">genotyping</a> may be useful to assess risk of <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> expansion upon transmission. See <a href="#fragilex.Anticipation">Anticipation</a>.</p></div></div><div id="fragilex.Clinical_Characteristics"><h2 id="_fragilex_Clinical_Characteristics_">Clinical Characteristics</h2><div id="fragilex.Clinical_Description"><h3>Clinical Description</h3><div id="fragilex.Males_with_Fragile_X_Syndrome_F"><h4>Males with Fragile X Syndrome (Full-Mutation Alleles)</h4><p>The phenotypic features of males with fragile X syndrome (FXS) vary in relation to puberty [<a class="bk_pop" href="#fragilex.REF.kidd.2014.995">Kidd et al 2014</a>].</p><p><b>Prepubertal features</b></p><ul><li class="half_rhythm"><div><b>Medical problems in infancy and childhood</b> include hypotonia, gastroesophageal reflux, strabismus, seizures, sleep disorders, joint laxity, <i>pes planus</i>, scoliosis, and recurrent otitis media. Excessive softness and smoothness of the skin also have been noted.</div></li><li class="half_rhythm"><div><b>Normal growth</b> is typical but large occipitofrontal head circumference (&#x0003e;50th percentile) is often seen.</div></li><li class="half_rhythm"><div><b>Delayed attainment of motor milestones and speech</b> is apparent in the first several years of life. Developmental milestones (usual age of attainment in boys):</div><ul><li class="half_rhythm"><div>Sit alone (10 months)</div></li><li class="half_rhythm"><div>Walk (20.6 months)</div></li><li class="half_rhythm"><div>First clear words (20 months)</div></li></ul></li><li class="half_rhythm"><div><b>Intellectual disability.</b> The mean IQ has been reported as 40-45 with a range from less than 10 to within the normal range [<a class="bk_pop" href="#fragilex.REF.sansone.2014.16">Sansone et al 2014</a>].</div></li><li class="half_rhythm"><div><b>Behavior</b> is a prominent issue in males and some females with FXS of all ages. Behavior issues can include attention-deficit/hyperactivity disorder (ADHD) symptoms: hyperactivity, problems with impulse control, distractibility stereotypies such as hand flapping, tactile defensiveness, anxiety, shyness, poor eye contact (gaze aversion), perseverative speech, temper tantrums, irritability, aggression, and self-injurious behavior such as hand biting. The behaviors tend to evolve over time, becoming more obvious, with reduced responsiveness and activity sometimes seen in children before age two years, and then progressively increasing hyperactivity and ADHD symptoms with anxiety and irritable behaviors emerging (to varying degrees) during childhood [<a class="bk_pop" href="#fragilex.REF.berrykravis.2012.843016">Berry-Kravis et al 2012</a>].</div></li><li class="half_rhythm"><div><b>Autism spectrum disorder (ASD)</b> is present in 50%-70% of individuals with FXS and when present, tends to be associated with more severe behavioral issues and an increased rate of seizures [<a class="bk_pop" href="#fragilex.REF.kidd.2019">Kidd et al 2019</a>].</div></li><li class="half_rhythm"><div><b>Physical features</b> involving the craniofacies (long face, prominent forehead, large ears, and prominent jaw) not readily recognizable in the preschool-age child become more obvious with age. Only a subset of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have typical physical features of FXS and presence of these is not reliable for diagnosis.</div></li></ul><p><b>Postpubertal features</b></p><ul><li class="half_rhythm"><div><b>Medical problems</b> including mitral valve prolapse and aortic root dilatation have been noted, most commonly in adults with FXS.</div></li><li class="half_rhythm"><div><b>Anxiety and irritable/aggressive behavior</b> may increase during or after puberty. Anxiety, including social phobia and specific phobias, anticipatory anxiety, performance anxiety, and separation anxiety, as well as generalized anxiety, is very common in FXS and often disabling, having been reported by caregivers as the most disabling problem for individuals with FXS [<a class="bk_pop" href="#fragilex.REF.weber.2019.e18">Weber et al 2019</a>].</div></li><li class="half_rhythm"><div><b>Macroorchidism</b> may be obvious earlier in childhood but is identified in essentially all males after completion of puberty.</div></li></ul></div><div id="fragilex.Females_with_FXS_Heterozygous_f"><h4>Females with FXS (Heterozygous for Full-Mutation Alleles)</h4><p>The physical and behavioral features seen in males with FXS have been reported in females <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for the full mutation, but with lower frequency and milder involvement [<a class="bk_pop" href="#fragilex.REF.bartholomay.2019">Bartholomay et al 2019</a>].</p></div><div id="fragilex.Fragile_XAssociated_TremorAtaxi"><h4>Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS)</h4><p>FXTAS is characterized by late-onset progressive cerebellar ataxia and intention tremor in persons who have an <i>FMR1</i> <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> [<a class="bk_pop" href="#fragilex.REF.hagerman.2016.403">Hagerman &#x00026; Hagerman 2016</a>].</p><p>Onset is typically between ages 60 and 65 years. The age of onset and progression of symptoms of FXTAS vary significantly among individuals. Both age of onset and disease severity are related to repeat length, sex, and other features.</p><p>The first sign of FXTAS is typically tremor followed by ataxia and cognitive impairment [<a class="bk_pop" href="#fragilex.REF.bourgeois.2016.913">Bourgeois 2016</a>, <a class="bk_pop" href="#fragilex.REF.hall.2018">Hall &#x00026; Berry-Kravis 2018</a>].</p><ul><li class="half_rhythm"><div>Ataxia can lead to gait and postural instability with most individuals needing a walking aid within ten years of diagnosis.</div></li><li class="half_rhythm"><div>Cognitive impairment typically starts with executive function impairment and expands to other domains such as working memory and information processing speed. Almost half of individuals with FXTAS meet criteria for dementia.</div></li></ul><p>Other findings include short-term memory loss, parkinsonism, peripheral neuropathy and neuropathic pain, lower-limb proximal muscle weakness, and autonomic dysfunction [<a class="bk_pop" href="#fragilex.REF.hagerman.2016.403">Hagerman &#x00026; Hagerman 2016</a>, <a class="bk_pop" href="#fragilex.REF.hall.2016.578">Hall et al 2016</a>].</p><p>Psychiatric disorders are common and include anxiety, irritability, agitation, hostility, obsessive-compulsive disorder, apathy, and depression [<a class="bk_pop" href="#fragilex.REF.seritan.2013.59">Seritan et al 2013</a>].</p><p>Both males and females with a <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> are at risk for FXTAS. Increasing premutation repeat lengths correlate with increasing likelihood of developing FXTAS [<a class="bk_pop" href="#fragilex.REF.tassone.2007.566">Tassone et al 2007</a>, <a class="bk_pop" href="#fragilex.REF.leehey.2008.1397">Leehey et al 2008</a>]. The <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> in individuals older than age 50 years is lower in females (16.5%) than in males (45.5%) [<a class="bk_pop" href="#fragilex.REF.rodriguezrevenga.2009.1359">Rodriguez-Revenga et al 2009</a>].</p><p><b>Males.</b> The prevalence of FXTAS is estimated at approximately 40% overall for males with a <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> who are older than age 50 years [<a class="bk_pop" href="#fragilex.REF.hagerman.2016.403">Hagerman &#x00026; Hagerman 2016</a>]. Penetrance in males is related to age (see <a class="figpopup" href="/books/NBK1384/table/fragilex.T.risk_for_fxtas_by_age_in_male/?report=objectonly" target="object" rid-figpopup="figfragilexTriskforfxtasbyageinmale" rid-ob="figobfragilexTriskforfxtasbyageinmale">Table 2</a>) and repeat length.</p><div id="fragilex.T.risk_for_fxtas_by_age_in_male" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Risk for FXTAS by Age in Males with an <i>FMR1</i> Premutation</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1384/table/fragilex.T.risk_for_fxtas_by_age_in_male/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fragilex.T.risk_for_fxtas_by_age_in_male_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_fragilex.T.risk_for_fxtas_by_age_in_male_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Age in Years</th><th id="hd_h_fragilex.T.risk_for_fxtas_by_age_in_male_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Risk</th></tr></thead><tbody><tr><td headers="hd_h_fragilex.T.risk_for_fxtas_by_age_in_male_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">50-59</td><td headers="hd_h_fragilex.T.risk_for_fxtas_by_age_in_male_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">17%</td></tr><tr><td headers="hd_h_fragilex.T.risk_for_fxtas_by_age_in_male_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">60-69</td><td headers="hd_h_fragilex.T.risk_for_fxtas_by_age_in_male_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">38%</td></tr><tr><td headers="hd_h_fragilex.T.risk_for_fxtas_by_age_in_male_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">70-79</td><td headers="hd_h_fragilex.T.risk_for_fxtas_by_age_in_male_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">47%</td></tr><tr><td headers="hd_h_fragilex.T.risk_for_fxtas_by_age_in_male_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02265;80</td><td headers="hd_h_fragilex.T.risk_for_fxtas_by_age_in_male_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">75%</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Adapted from <a class="bk_pop" href="#fragilex.REF.grigsby.2005">Grigsby et al [2005]</a></p></div></dd></dl></div></div></div><p><b>Females.</b> While FXTAS is more difficult to ascertain in females because of milder clinical presentation, prevalence estimates range from approximately 16% to 20% of female <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> heterozygotes [<a class="bk_pop" href="#fragilex.REF.hagerman.2016.403">Hagerman &#x00026; Hagerman 2016</a>].</p></div><div id="fragilex.Fragile_XAssociated_Primary_Ova"><h4>Fragile X-Associated Primary Ovarian Insufficiency (FXPOI)</h4><p>FXPOI, defined as hypergonadotropic hypogonadism before age 40 years, has been observed in 20% of women who carry a <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> compared to 1% in the general population [<a class="bk_pop" href="#fragilex.REF.sherman.2000.189">Sherman 2000</a>].</p><ul><li class="half_rhythm"><div>Ovarian insufficiency has occurred as early as age 11 years and can present with primary amenorrhea and delayed puberty.</div></li><li class="half_rhythm"><div>Women with FXPOI have high rates of infertility and menopausal-type symptoms, including vasomotor symptoms, mood changes, and vaginal dryness.</div><ul><li class="half_rhythm"><div>In contrast to menopause, ovarian function in women with POI is more erratic and unpredictable, so that some women continue to have irregular ovulation and menses for years after diagnosis. Some women are completely amenorrheic.</div></li><li class="half_rhythm"><div>The diagnosis of POI does not eliminate the possibility of subsequent conception. It is estimated that up to 12.6% of women conceive after a diagnosis of FXPOI [<a class="bk_pop" href="#fragilex.REF.hipp.2016.993">Hipp et al 2016</a>]. See <a class="bk_pop" href="#fragilex.REF.fink.2018.529">Fink et al [2018]</a> for a review.</div></li></ul></li><li class="half_rhythm"><div>Women with FXPOI are at risk of long-term health sequelae from a hypoestrogenic environment. These include osteoporosis and cardiovascular disease.</div></li><li class="half_rhythm"><div>Women with POI (including those with FXPOI) are at increased risk of developing thyroid disease.</div></li></ul><p>The earlier findings that alleles in the high normal and intermediate range conferred an increased risk for FXPOI [<a class="bk_pop" href="#fragilex.REF.bretherick.2005.376">Bretherick et al 2005</a>, <a class="bk_pop" href="#fragilex.REF.bodega.2006.952">Bodega et al 2006</a>] have not been supported by more recent robust studies [<a class="bk_pop" href="#fragilex.REF.voorhuis.2014.1585">Voorhuis et al 2014</a>, <a class="bk_pop" href="#fragilex.REF.schufreider.2015.2686">Schufreider et al 2015</a>].</p><p>Women with full-mutation alleles are not at increased risk for FXPOI, nor do they have signs of diminished ovarian reserve [<a class="bk_pop" href="#fragilex.REF.avraham.2017.1508">Avraham et al 2017</a>].</p></div><div id="fragilex.Other_Fragile_XAssociated_Pheno"><h4>Other Fragile X-Associated Phenotypes</h4><p>In addition to FXTAS and FXPOI, the following have been reported in the literature (see <a class="bk_pop" href="#fragilex.REF.wheeler.2017.s172">Wheeler et al [2017]</a> for a review):</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Cognitive and behavioral challenges.</b> Preliminary studies of the correlation of <i>FMR1</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> size variations in the normal and <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> range suggested a possible relationship to mild intellectual disability in females [<a class="bk_pop" href="#fragilex.REF.allen.2005.435">Allen et al 2005</a>] and males [<a class="bk_pop" href="#fragilex.REF.loat.2006.555">Loat et al 2006</a>, <a class="bk_pop" href="#fragilex.REF.hagerman.2009.378">Hagerman et al 2009</a>]. Evidence also suggested an increased risk for autism spectrum disorder [<a class="bk_pop" href="#fragilex.REF.farzin.2006.s137">Farzin et al 2006</a>, <a class="bk_pop" href="#fragilex.REF.hagerman.2009.378">Hagerman et al 2009</a>] and neurodevelopmental diagnoses in individuals with a premutation [<a class="bk_pop" href="#fragilex.REF.bailey.2008.2060">Bailey et al 2008</a>, <a class="bk_pop" href="#fragilex.REF.renda.2014.326">Renda et al 2014</a>]. However, findings across studies have been contradictory, with some studies biased by assessment of individuals who had been clinically referred. Thus, additional studies are needed.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Neuropsychiatric issues.</b> Increased rates of anxiety, depression, and ADHD have been reported. Social phobia and social anxiety have also been reported. However, many studies on mental health outcomes are limited to women with a <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> who are mothers of children with FXS; thus, findings are likely confounded by the impact of elevated maternal stress on mental health [<a class="bk_pop" href="#fragilex.REF.wheeler.2017.s172">Wheeler et al 2017</a>], though some studies have indicated that the premutation confers a heightened susceptibility to stress and dysregulation of the hypothalamic-pituitary axis [<a class="bk_pop" href="#fragilex.REF.hartley.2012.53">Hartley et al 2012</a>, <a class="bk_pop" href="#fragilex.REF.seltzer.2012.612">Seltzer et al 2012</a>].</div><div class="half_rhythm">The term "fragile X-associated neuropsychiatric disorders" (FXAND) has been proposed to promote research into fully characterizing neuropsychiatric outcomes associated with the <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> [<a class="bk_pop" href="#fragilex.REF.hagerman.2018.564">Hagerman et al 2018</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Medical findings.</b> Some studies have reported elevated rates of hypertension, hypothyroidism, fibromyalgia, migraines, insomnia, sleep apnea, restless leg syndrome, central pain sensitivity syndrome, and autoimmune disorders in individuals with a <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> compared to those without a premutation [<a class="bk_pop" href="#fragilex.REF.hagerman.2016.403">Hagerman &#x00026; Hagerman 2016</a>]. However, these findings differ by investigator (reviewed in <a class="bk_pop" href="#fragilex.REF.wheeler.2014.30">Wheeler et al [2014]</a>). Unfortunately, most studies have been focused on women with a premutation and are based on questionnaires and chart reviews rather than objective medical examinations, which has created inconsistencies between research groups. Thus, the generalizability of these findings is unclear.</div><div class="half_rhythm">Elevated rates of neurologic findings, such as tremor and ataxia, have been reported in individuals with premutations who do not meet diagnostic criteria of FXTAS. A study of 110 daughters of men with FXTAS demonstrated an increased incidence of neurologic and psychiatric symptoms compared to controls, providing more evidence for such an association [<a class="bk_pop" href="#fragilex.REF.chonchaiya.2010.38">Chonchaiya et al 2010</a>].</div></li></ul></div></div><div id="fragilex.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>The <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of males with an <i>FMR1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> depends almost entirely on the nature of the variant; the phenotype of females with an <i>FMR1</i> pathogenic variant depends on both the nature of the <i>FMR1</i> variant and random <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a> (see <a class="figpopup" href="/books/NBK1384/table/fragilex.T.types_of_fmr1_repeat_expansio/?report=objectonly" target="object" rid-figpopup="figfragilexTtypesoffmr1repeatexpansio" rid-ob="figobfragilexTtypesoffmr1repeatexpansio">Table 3</a>).</p><div id="fragilex.T.types_of_fmr1_repeat_expansio" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Types of <i>FMR1</i> Repeat Expansion Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1384/table/fragilex.T.types_of_fmr1_repeat_expansio/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fragilex.T.types_of_fmr1_repeat_expansio_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_1" style="text-align:left;vertical-align:middle;">Variant Type</th><th id="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_2" style="text-align:left;vertical-align:middle;"># of CGG Trinucleotide Repeats</th><th id="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_3" style="text-align:left;vertical-align:middle;">Methylation Status of <i>FMR1</i></th><th id="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_4" colspan="2" scope="colgroup" rowspan="1" style="text-align:center;vertical-align:middle;">Clinical Status</th></tr><tr><th headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_4" id="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Male</th><th headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_4" id="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Female</th></tr></thead><tbody><tr><td headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Premutation</b></td><td headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~55-200</td><td headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unmethylated</td><td headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_4 hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">At risk for FXTAS&#x000a0;<sup>1</sup></td><td headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_4 hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>At risk for FXPOI &#x00026; FXTAS</div></li><li class="half_rhythm"><div>Potential &#x02191; risk of other fragile X-assoc disorders&#x000a0;<sup>1</sup></div></li></ul>
</td></tr><tr><td headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Full mutation</b></td><td headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;200</td><td headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Completely methylated</td><td headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_4 hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100% have ID.</td><td headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_4 hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~50% w/ID, ~50% normal intellect</td></tr><tr><td headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Repeat size <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a></b></td><td headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Varies between <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> &#x00026; full mutation in different cell lines</td><td headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Partial: unmethylated in <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> cell line; methylated in full-mutation cell line</td><td headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_4 hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_2_1" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">Nearly 100% have ID; may be higher functioning&#x000a0;<sup>2</sup> than males w/full mutation.</td><td headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_4 hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_2_2" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;">Highly variable: ranges from normal intellect to <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a></td></tr><tr><td headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Methylation <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a></b></td><td headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;200</td><td headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Partial: mixture of methylated &#x00026; unmethylated cell lines</td></tr><tr><td headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Unmethylated full mutation</b></td><td headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;200</td><td headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unmethylated</td><td headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_4 hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>ID, if present, is typically high functioning.</div></li><li class="half_rhythm"><div>May have anxiety &#x00026;/or behavioral issues even w/out ID</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">ID = intellectual disability</p></div></dd><dt>1. </dt><dd><div id="fragilex.TF.3.1"><p class="no_margin">Both males and females with premutations have been reported to have slightly elevated rates of some manifestations of fragile X syndrome, such as facial features, behavioral problems, learning disabilities, ADHD, and anxiety [<a class="bk_pop" href="#fragilex.REF.riddle.1998.590">Riddle et al 1998</a>, <a class="bk_pop" href="#fragilex.REF.bourgeois.2009.852">Bourgeois et al 2009</a>, <a class="bk_pop" href="#fragilex.REF.hunter.2009.79">Hunter et al 2009</a>, <a class="bk_pop" href="#fragilex.REF.chonchaiya.2010.38">Chonchaiya et al 2010</a>]. Some studies also indicate an increased rate of additional outcomes, such as depression, pain disorders, autoimmune disorders, and other health outcomes [<a class="bk_pop" href="#fragilex.REF.wheeler.2017.s172">Wheeler et al 2017</a>, <a class="bk_pop" href="#fragilex.REF.hagerman.2018.564">Hagerman et al 2018</a>].</p></div></dd><dt>2. </dt><dd><div id="fragilex.TF.3.2"><p class="no_margin"><i>FMR1</i> pathogenic variants are complex alterations involving nonclassic <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-<a class="def" href="/books/n/gene/glossary/def-item/inactivating/">inactivating</a> variants (<a class="def" href="/books/n/gene/glossary/def-item/trinucleotide-repeat/">trinucleotide repeat</a> expansion) and abnormal gene <a class="def" href="/books/n/gene/glossary/def-item/methylation/">methylation</a>. This complexity at the gene level affects production of the <i>FMR1</i> protein (FMRP) and may result in an atypical presentation in which <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals occasionally have an IQ above 70, the traditional demarcation denoting intellectual disability (previously referred to as mental retardation).</p></div></dd></dl></div></div></div><p><b>Premutation.</b> Males and females who have an <i>FMR1</i> <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> have normal intellect and appearance. As noted in <a class="figpopup" href="/books/NBK1384/table/fragilex.T.types_of_fmr1_repeat_expansio/?report=objectonly" target="object" rid-figpopup="figfragilexTtypesoffmr1repeatexpansio" rid-ob="figobfragilexTtypesoffmr1repeatexpansio">Table 3</a>, footnote 1, a subset of individuals with a premutation may have subtle intellectual or behavioral symptoms including learning difficulties or social anxiety. It is currently unclear whether these reported symptoms result from the premutation or are the product of an ascertainment bias toward identification of individuals with premutations who manifest intellectual or behavioral symptoms. The symptoms are usually not socially debilitating.</p><ul><li class="half_rhythm"><div>For FXTAS, repeat size is correlated with severity: higher repeat size is associated with greater motor impairment (tremor, ataxia, and parkinsonism), more severe peripheral neuropathy, higher number of intranuclear inclusions in the brain, MRI abnormalities (reduced cerebellar volume and increased ventricular volume and whole-brain white matter hyperintensity), and earlier age of onset [<a class="bk_pop" href="#fragilex.REF.hall.2018">Hall &#x00026; Berry-Kravis 2018</a>].</div></li><li class="half_rhythm"><div>It is estimated that 21% of women who carry a <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> develop FXPOI [<a class="bk_pop" href="#fragilex.REF.sherman.2005">Sherman 2005</a>]. The association between repeat size of the premutation <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> and FXPOI is nonlinear; women with 80-99 repeats are at greatest risk for FXPOI [<a class="bk_pop" href="#fragilex.REF.sherman.2005">Sherman 2005</a>] (see <a class="figpopup" href="/books/NBK1384/table/fragilex.T.odds_ratios_for_fxpoi_by_prem/?report=objectonly" target="object" rid-figpopup="figfragilexToddsratiosforfxpoibyprem" rid-ob="figobfragilexToddsratiosforfxpoibyprem">Table 4</a>).</div></li></ul><ul><li class="half_rhythm"><div>Additional studies indicate other vulnerabilities for the mid-repeat ranges of the <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> in women, such as an increased risk of psychological symptoms [<a class="bk_pop" href="#fragilex.REF.loesch.2015.173">Loesch et al 2015</a>] and vulnerability to stress [<a class="bk_pop" href="#fragilex.REF.seltzer.2012.612">Seltzer et al 2012</a>]. It is unclear whether these relationships are due to the premutation itself or to the higher level of hormonal dysfunction in FXPOI seen in the mid-repeat ranges.</div></li></ul><div id="fragilex.T.odds_ratios_for_fxpoi_by_prem" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Odds Ratios for FXPOI by Premutation Size</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1384/table/fragilex.T.odds_ratios_for_fxpoi_by_prem/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fragilex.T.odds_ratios_for_fxpoi_by_prem_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_fragilex.T.odds_ratios_for_fxpoi_by_prem_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Premutation Size in CGG Repeats</th><th id="hd_h_fragilex.T.odds_ratios_for_fxpoi_by_prem_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Odds Ratio for FXPOI</th></tr></thead><tbody><tr><td headers="hd_h_fragilex.T.odds_ratios_for_fxpoi_by_prem_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">59-79</td><td headers="hd_h_fragilex.T.odds_ratios_for_fxpoi_by_prem_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">6.9</td></tr><tr><td headers="hd_h_fragilex.T.odds_ratios_for_fxpoi_by_prem_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">80-99</td><td headers="hd_h_fragilex.T.odds_ratios_for_fxpoi_by_prem_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">25.1</td></tr><tr><td headers="hd_h_fragilex.T.odds_ratios_for_fxpoi_by_prem_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;100</td><td headers="hd_h_fragilex.T.odds_ratios_for_fxpoi_by_prem_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">16.4</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin"><a class="bk_pop" href="#fragilex.REF.sherman.2005">Sherman [2005]</a></p></div></dd></dl></div></div></div><p><b>Full mutation.</b> Males who have a full <i>FMR1</i> mutation generally have moderate-to-severe intellectual disability and may or may not have a distinctive appearance.</p><p>Approximately 50% of females who have a full <i>FMR1</i> mutation are intellectually disabled; however, they are usually less severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> than males with a full mutation. Conversely, approximately 50% of females who are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for the full mutation are intellectually normal. However, many of those with IQ in the normal range will have substantial issues with learning disability, ADHD, anxiety, and/or social-emotional dysfunction. The variability among females is believed to result from the ratio in the brain of active X chromosomes with the <i>FMR1</i> full mutation to inactive X chromosomes with the normal <i>FMR1</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>.</p><p><b>Mosaicism.</b> Mosaicism of <i>FMR1</i> variants is common. Such <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a> may be (1) "repeat size mosaicism," in which both full mutations and premutations are present (also termed "full-mutation/<a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> mosaicism"), or (2) <a class="def" href="/books/n/gene/glossary/def-item/methylation/">methylation</a> mosaicism, in which full mutations have varying degrees of methylation.</p><p>Although some data suggest that individuals with repeat size <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a> or <a class="def" href="/books/n/gene/glossary/def-item/methylation/">methylation</a> mosaicism perform at a higher intellectual level than those with completely methylated full mutations, such individuals are usually intellectually disabled.</p><p>Rarely, individuals with <a class="def" href="/books/n/gene/glossary/def-item/methylation/">methylation</a> <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a> or completely unmethylated full mutations and normal intellect have been reported. The milder <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> appears to be related to <i>FMR1</i> protein (FMRP) production arising from transcription of unmethylated alleles [<a class="bk_pop" href="#fragilex.REF.tassone.1999.250">Tassone et al 1999</a>]. Presumably, these individuals produce at least some FMRP because <i>FMR1</i> is unmethylated. The existence of these exceptional individuals suggests that repeat expansion and methylation of the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> are not absolutely coupled. <a class="bk_pop" href="#fragilex.REF.han.2006.1463">Han et al [2006]</a> reported a male with complex <i>FMR1</i> mosaicism (full mutation, <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a>, and <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>) with only learning disability, which raises issues concerning gene and protein expression in <i>FMR1</i>-related phenotypes.</p></div><div id="fragilex.Anticipation"><h3>Anticipation</h3><p>Fragile X syndrome (FXS) is a <a class="def" href="/books/n/gene/glossary/def-item/trinucleotide-repeat/">trinucleotide repeat</a> disorder that may demonstrate <a class="def" href="/books/n/gene/glossary/def-item/anticipation/">anticipation</a> in some families. Typically, anticipation occurs when less severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with a <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> or mosaic mutation transmit unstable <i>FMR1</i> alleles to their offspring (e.g., transmission from a grandfather who carries a premutation to his daughter, whose premutation expands into a full mutation when she transmits it to her son, who has intellectual disability as a result). However, the anticipation found in families with members affected with FXS is not classic, as is that found in, for example, <a href="/books/n/gene/myotonic-d/">myotonic dystrophy type 1</a>, where the disease itself becomes worse and with earlier age at onset with advancing generations. Many families transmit premutation <i>FMR1</i> alleles for generations with little or no presentation of clinical symptoms until a full mutation is produced, resulting in an individual with a diagnosis of FXS. The form of anticipation in FXS is increasing numbers of individuals with FXS with advancing generations.</p><p><b>AGG <a class="def" href="/books/n/gene/glossary/def-item/trinucleotide-repeat/">trinucleotide repeat</a> <a class="def" href="/books/n/gene/glossary/def-item/genotyping/">genotyping</a>.</b> In stable, normal alleles, the CGG region is interrupted by an AGG triplet at every nine to ten CGG repeats. AGG genotyping may be performed to determine the number and location of AGG trinucleotide interruptions within the CGG repeat. The number and position of AGG trinucleotide repeats are known to be important in the overall stability of the CGG repeat sequence. Recent results have linked the presence of an AGG interruption with a reduced risk of transmission to a full mutation in CGG repeat ranges below 100 [<a class="bk_pop" href="#fragilex.REF.yrigollen.2012.729">Yrigollen et al 2012</a>, <a class="bk_pop" href="#fragilex.REF.yrigollen.2014.153">Yrigollen et al 2014</a>, <a class="bk_pop" href="#fragilex.REF.nolin.2015.358">Nolin et al 2015</a>]. Direct testing for the AGG triplets is available clinically, though it is not routinely performed, and its clinical usefulness is not yet fully understood. It may help predict risk of expansions from premutations of fewer than 100 repeats [<a class="bk_pop" href="#fragilex.REF.yrigollen.2012.729">Yrigollen et al 2012</a>, <a class="bk_pop" href="#fragilex.REF.nolin.2015.358">Nolin et al 2015</a>].</p><p>The impact of AGG interruptions on clinical outcomes in individuals with a <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> is unknown. Conflicting results regarding AGG interruptions and FXPOI have been published [<a class="bk_pop" href="#fragilex.REF.allen.2018.292">Allen et al 2018</a>, <a class="bk_pop" href="#fragilex.REF.lekovich.2018.957">Lekovich et al 2018</a>].</p></div><div id="fragilex.Nomenclature"><h3>Nomenclature</h3><p>Fragile X syndrome has also been referred to as FXS, fragile X mental retardation, marker X syndrome, and Martin-Bell syndrome.</p><p><i>FMR1</i> primary ovarian insufficiency has also been referred to as <i>FMR1</i>-related premature ovarian failure.</p></div><div id="fragilex.Prevalence"><h3>Prevalence</h3><p><b>Fragile X syndrome.</b> Prevalence estimates of males with fragile X syndrome (FXS) have been revised downward since the isolation of <i>FMR1</i> in 1991. Original estimates of 80:100,000 males were based on detection of fragile sites on <a class="def" href="/books/n/gene/glossary/def-item/cytogenetic/">cytogenetic</a> studies and resulted in an overestimate because fragile sites other than the one associated with <i>FMR1</i> (FRAXA) were detected and included in the estimate. More recent studies using <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of <i>FMR1</i> have estimated a prevalence of 16 to 25 per 100,000 males with FXS (using intellectual disability as the hallmark clinical finding) [<a class="bk_pop" href="#fragilex.REF.de_vries.1997.660">de Vries et al 1997</a>]. In an analysis of 36,124 newborn males, <a class="bk_pop" href="#fragilex.REF.coffee.2009.503">Coffee et al [2009]</a> determined that the incidence of a full mutation (and hence, FXS) was approximately 19:100,000 males. A meta-analysis estimated prevalence of the full mutation as 14:100,000 [<a class="bk_pop" href="#fragilex.REF.hunter.2014.1648">Hunter et al 2014</a>].</p><p>The prevalence of females with FXS is presumed to be approximately one half the male prevalence due to reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>.</p><p>FXS is the most common known single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> cause of autism spectrum disorder (ASD) and accounts for about 2%-3% of all ASD cases [<a class="bk_pop" href="#fragilex.REF.kaufmann.2017.s194">Kaufmann et al 2017</a>].</p><p><b><i>FMR1</i> <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a>.</b> A meta-analysis estimated the prevalence of the premutation <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> at 117:100,0000 males and 344:100,000 females [<a class="bk_pop" href="#fragilex.REF.hunter.2014.1648">Hunter et al 2014</a>]. However, a study of a population-based sample of 19,996 males and females resulted in higher prevalence estimates for the premutation: 345:100,000 males and 677:100,000 females [<a class="bk_pop" href="#fragilex.REF.maenner.2013.466">Maenner et al 2013</a>].</p><p><b>FXTAS.</b> After accounting for the prevalence of the <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> among males, the frequency of up to 70 repeat alleles, and <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> of FXTAS in males with larger premutation alleles (33%), the prevalence of FXTAS in males in the US has been estimated at 1:4,848 [<a class="bk_pop" href="#fragilex.REF.hantash.2011.39">Hantash et al 2011</a>]. The prevalence in women is more difficult to calculate given the variable presentation.</p><p>An estimated 2%-4% of men with adult-onset cerebellar ataxia who represent <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases (i.e., a single occurrence in a family) have a <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> in <i>FMR1</i> [<a class="bk_pop" href="#fragilex.REF.brussino.2005.145">Brussino et al 2005</a>, <a class="bk_pop" href="#fragilex.REF.cellini.2006.1135">Cellini et al 2006</a>]. There have been no similar studies of women with adult-onset cerebellar ataxia.</p><p><b>FXPOI.</b> The prevalence of FXPOI in women in the US has been estimated at 1:3,560 based on the prevalence of the <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> and <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> of FXPOI in women with the premutation (20%) [<a class="bk_pop" href="#fragilex.REF.hantash.2011.39">Hantash et al 2011</a>]. The <i>FMR1</i> premutation accounts for approximately 3.2% of <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> cases of POI and 11% of <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> cases (reviewed in <a class="bk_pop" href="#fragilex.REF.fink.2018.529">Fink et al [2018]</a>).</p></div></div><div id="fragilex.Genetically_Related_Allelic_Dis"><h2 id="_fragilex_Genetically_Related_Allelic_Dis_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than FXS, FXTAS, FXPOI, and the other fragile X-associated phenotypes discussed in this <i>GeneReview</i> are known to be associated with pathogenic variants in <i>FMR1</i>.</p></div><div id="fragilex.Differential_Diagnosis"><h2 id="_fragilex_Differential_Diagnosis_">Differential Diagnosis</h2><p><b>Developmental delay /</b>
<b>intellectual disability (DD/ID).</b> The signs of fragile X syndrome (FXS) in early childhood are nonspecific, with DD being an almost universal manifestation among <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals. Any child (male or female) with delay of speech, language, or motor development of unknown etiology should be considered for fragile X testing, especially in the presence of a family history of ID and a consistent physical and behavioral <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>, and the absence of structural abnormalities of the brain or other birth defects [<a class="bk_pop" href="#fragilex.REF.curry.1997.468">Curry et al 1997</a>, Moeschler &#x00026; Shevell 2006]. When fragile X <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> is used regularly in this large and loosely defined group of unselected males with ID, the yield of positive test results is relatively low (~3%-6%) [<a class="bk_pop" href="#fragilex.REF.curry.1997.468">Curry et al 1997</a>, <a class="bk_pop" href="#fragilex.REF.shevell.2003.367">Shevell et al 2003</a>]. In a more recent study, <a class="bk_pop" href="#fragilex.REF.rauch.2006.2063">Rauch et al [2006]</a> found the yield to be 1.2%.</p><p>Because <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> abnormalities and copy number variants have been identified as frequently or more frequently than <i>FMR1</i> pathogenic variants in individuals with DD or ID who are referred for fragile X testing, microarray testing should be performed as a part of the laboratory evaluation [<a class="bk_pop" href="#fragilex.REF.manning.2010.742">Manning &#x00026; Hudgins 2010</a>, <a class="bk_pop" href="#fragilex.REF.miller.2010.749">Miller et al 2010</a>].</p><p>Conditions to be considered in the differential diagnosis of FXS include those summarized in <a class="figpopup" href="/books/NBK1384/table/fragilex.T.disorders_to_consider_in_the/?report=objectonly" target="object" rid-figpopup="figfragilexTdisorderstoconsiderinthe" rid-ob="figobfragilexTdisorderstoconsiderinthe">Table 5</a>.</p><div id="fragilex.T.disorders_to_consider_in_the" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p>Disorders to Consider in the Differential Diagnosis of Fragile X Syndrome</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1384/table/fragilex.T.disorders_to_consider_in_the/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fragilex.T.disorders_to_consider_in_the_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_fragilex.T.disorders_to_consider_in_the_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_fragilex.T.disorders_to_consider_in_the_1_1_1_1" style="text-align:left;vertical-align:middle;">Disorder</th><th id="hd_h_fragilex.T.disorders_to_consider_in_the_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_fragilex.T.disorders_to_consider_in_the_1_1_1_2" style="text-align:left;vertical-align:middle;">Gene /<br />Genetic Mechanism</th><th id="hd_h_fragilex.T.disorders_to_consider_in_the_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_fragilex.T.disorders_to_consider_in_the_1_1_1_3" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_fragilex.T.disorders_to_consider_in_the_1_1_1_4" colspan="2" scope="colgroup" rowspan="1" style="text-align:center;vertical-align:middle;">Clinical Features of Differential Diagnosis Disorder</th></tr><tr><th headers="hd_h_fragilex.T.disorders_to_consider_in_the_1_1_1_4" id="hd_h_fragilex.T.disorders_to_consider_in_the_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Overlapping w/FXS</th><th headers="hd_h_fragilex.T.disorders_to_consider_in_the_1_1_1_4" id="hd_h_fragilex.T.disorders_to_consider_in_the_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Distinguishing from FXS</th></tr></thead><tbody><tr><td headers="hd_h_fragilex.T.disorders_to_consider_in_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/sotos/">Sotos syndrome</a></td><td headers="hd_h_fragilex.T.disorders_to_consider_in_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>NSD1</i></td><td headers="hd_h_fragilex.T.disorders_to_consider_in_the_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_fragilex.T.disorders_to_consider_in_the_1_1_1_4 hd_h_fragilex.T.disorders_to_consider_in_the_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Typical facial appearance</div></li><li class="half_rhythm"><div>Mild-to-severe learning disability</div></li><li class="half_rhythm"><div>Behavior problems</div></li><li class="half_rhythm"><div>Seizures</div></li></ul>
</td><td headers="hd_h_fragilex.T.disorders_to_consider_in_the_1_1_1_4 hd_h_fragilex.T.disorders_to_consider_in_the_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Overgrowth</div></li><li class="half_rhythm"><div>Congenital cardiac anomalies</div></li><li class="half_rhythm"><div>Neonatal jaundice</div></li><li class="half_rhythm"><div>Renal anomalies</div></li><li class="half_rhythm"><div>Scoliosis</div></li></ul>
</td></tr><tr><td headers="hd_h_fragilex.T.disorders_to_consider_in_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/pws/">Prader-Willi syndrome</a><br />(PWS)</td><td headers="hd_h_fragilex.T.disorders_to_consider_in_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 1</td><td headers="hd_h_fragilex.T.disorders_to_consider_in_the_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 2</td><td headers="hd_h_fragilex.T.disorders_to_consider_in_the_1_1_1_4 hd_h_fragilex.T.disorders_to_consider_in_the_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>A small subset of those w/FXS have the hyperphagia &#x00026; obesity characteristic of PWS&#x000a0;<sup>3</sup></div></li><li class="half_rhythm"><div>DD &#x00026; cognitive impairment</div></li><li class="half_rhythm"><div>Temper tantrums, stubbornness, manipulative behavior, &#x00026; obsessive-compulsive traits</div></li></ul>
</td><td headers="hd_h_fragilex.T.disorders_to_consider_in_the_1_1_1_4 hd_h_fragilex.T.disorders_to_consider_in_the_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Hypogonadism (genital hypoplasia, incomplete puberty &#x00026;, in most, infertility)</div></li><li class="half_rhythm"><div>Characteristic PWS facial appearance</div></li><li class="half_rhythm"><div>Short stature</div></li></ul>
</td></tr><tr><td headers="hd_h_fragilex.T.disorders_to_consider_in_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Autism<br />spectrum<br />disorder</td><td headers="hd_h_fragilex.T.disorders_to_consider_in_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 4</td><td headers="hd_h_fragilex.T.disorders_to_consider_in_the_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR<br />AD<br />XL<br />Mu</td><td headers="hd_h_fragilex.T.disorders_to_consider_in_the_1_1_1_4 hd_h_fragilex.T.disorders_to_consider_in_the_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Autistic-like behavior</td><td headers="hd_h_fragilex.T.disorders_to_consider_in_the_1_1_1_4 hd_h_fragilex.T.disorders_to_consider_in_the_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Absence of cognitive &#x00026; physical features of FXS</td></tr><tr><td headers="hd_h_fragilex.T.disorders_to_consider_in_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">ADHD</td><td headers="hd_h_fragilex.T.disorders_to_consider_in_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 5</td><td headers="hd_h_fragilex.T.disorders_to_consider_in_the_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD<br />Mu</td><td headers="hd_h_fragilex.T.disorders_to_consider_in_the_1_1_1_4 hd_h_fragilex.T.disorders_to_consider_in_the_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hyperactivity</td><td headers="hd_h_fragilex.T.disorders_to_consider_in_the_1_1_1_4 hd_h_fragilex.T.disorders_to_consider_in_the_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Absence of cognitive &#x00026; physical features of FXS</td></tr><tr><td headers="hd_h_fragilex.T.disorders_to_consider_in_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Fragile XE syndrome (FRAXE)<br />(OMIM <a href="https://omim.org/entry/309548" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">309548</a>)</td><td headers="hd_h_fragilex.T.disorders_to_consider_in_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>AFF2</i>&#x000a0;<sup>6</sup><br />(<i>FMR2</i>)</td><td headers="hd_h_fragilex.T.disorders_to_consider_in_the_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">XL</td><td headers="hd_h_fragilex.T.disorders_to_consider_in_the_1_1_1_4 hd_h_fragilex.T.disorders_to_consider_in_the_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mild ID (not as severe as is typically seen in FXS)</td><td headers="hd_h_fragilex.T.disorders_to_consider_in_the_1_1_1_4 hd_h_fragilex.T.disorders_to_consider_in_the_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Absence of physical features characteristic of FXS</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; ADHD = attention-deficit/hyperactivity disorder; AR = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>; DD = developmental delay; FXS = fragile X syndrome; MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a>; Mu = <a class="def" href="/books/n/gene/glossary/def-item/multifactorial/">multifactorial</a>; XL = <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a></p></div></dd><dt>1. </dt><dd><div id="fragilex.TF.5.1"><p class="no_margin">PWS is caused by an absence of expression of <a class="def" href="/books/n/gene/glossary/def-item/imprinted/">imprinted</a> genes in the paternally derived PWS/Angelman syndrome (AS) region (i.e., 15q11.2-q13) of <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 15 by one of several genetic mechanisms (paternal <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>, maternal <a class="def" href="/books/n/gene/glossary/def-item/uniparental-disomy/">uniparental disomy</a> 15, and rarely an <a class="def" href="/books/n/gene/glossary/def-item/imprinting/">imprinting</a> defect).</p></div></dd><dt>2. </dt><dd><div id="fragilex.TF.5.2"><p class="no_margin">The risk to the sibs of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child of having PWS depends on the genetic mechanism that resulted in the absence of expression of the paternally contributed 15q11.2-q13 region.</p></div></dd><dt>3. </dt><dd><div id="fragilex.TF.5.3"><p class="no_margin">PWS is characterized by severe infantile hypotonia and feeding difficulties, followed by early-childhood onset of excessive eating and development of morbid obesity unless controlled.</p></div></dd><dt>4. </dt><dd><div id="fragilex.TF.5.4"><p class="no_margin">See OMIM <a href="https://omim.org/phenotypicSeries/PS209850" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PS209850</a> for a list of genes associated with this <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in OMIM.</p></div></dd><dt>5. </dt><dd><div id="fragilex.TF.5.5"><p class="no_margin">See OMIM <a href="https://omim.org/entry/143465" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">143465</a> for discussion of multiple loci associated with susceptibility to ADHD.</p></div></dd><dt>6. </dt><dd><div id="fragilex.TF.5.6"><p class="no_margin">FRAXA and FRAXE are distinct fragile sites, albeit in close proximity on the X <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a>. The genes spanning the two fragile sites are designated <i>FMR1</i> (FRAXA) and <i>AFF2</i> (FRAXE). However, the genes do not have any detectable similarity at the DNA level and the associated clinical entities are discrete.</p></div></dd></dl></div></div></div><p><b>Adult-onset neurologic disorders.</b> The differential diagnosis for FXTAS is broad. One group of 56 individuals had 98 different diagnoses prior to the diagnosis of FXTAS. Most of these were in the following categories: parkinsonism, tremor, ataxia, dementia, autonomic dysfunction, and stroke [<a class="bk_pop" href="#fragilex.REF.biancalana.2005.962">Biancalana et al 2005</a>, <a class="bk_pop" href="#fragilex.REF.hall.2005.299">Hall et al 2005</a>]. Neuronal intranuclear inclusion disease is associated with a CGG repeat in <i>NOTCH2NLC</i> and is similar in morphology and clinical presentation to FXTAS [<a class="bk_pop" href="#fragilex.REF.sone.2016.3170">Sone et al 2016</a>, <a class="bk_pop" href="#fragilex.REF.ishiura.2019.1222">Ishiura et al 2019</a>, <a class="bk_pop" href="#fragilex.REF.sone.2019.1215">Sone et al 2019</a>, <a class="bk_pop" href="#fragilex.REF.tian.2019.166">Tian et al 2019</a>]. See also <a href="/books/n/gene/ataxias/">Hereditary Ataxia Overview</a>.</p><p><b>Premature ovarian failure. </b>Differential diagnosis for irregular menstrual cycles beyond primary ovarian insufficiency (POI) can include polycystic ovary syndrome, thyroid disorders, and high prolactin. Once POI is diagnosed, there are other causes beyond the <i>FMR1</i> <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> to consider including Turner syndrome, autoimmune disorders, and past chemotherapy treatment.</p></div><div id="fragilex.Management"><h2 id="_fragilex_Management_">Management</h2><div id="fragilex.Evaluations_Following_Initial_D"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with an <i>FMR1</i> disorder, the evaluations summarized in <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>-specific <a class="figpopup" href="/books/NBK1384/table/fragilex.T.fragile_x_syndrome_recommende/?report=objectonly" target="object" rid-figpopup="figfragilexTfragilexsyndromerecommende" rid-ob="figobfragilexTfragilexsyndromerecommende">Tables 6</a>, <a class="figpopup" href="/books/NBK1384/table/fragilex.T.fragile_xassociated_tremorata/?report=objectonly" target="object" rid-figpopup="figfragilexTfragilexassociatedtremorata" rid-ob="figobfragilexTfragilexassociatedtremorata">7</a>, and <a class="figpopup" href="/books/NBK1384/table/fragilex.T.fmr1_primary_ovarian_insuffic/?report=objectonly" target="object" rid-figpopup="figfragilexTfmr1primaryovarianinsuffic" rid-ob="figobfragilexTfmr1primaryovarianinsuffic">8</a> (if not performed as part of the evaluation that led to diagnosis) are recommended. <b>For all phenotypes, consultation with a clinical geneticist and/or genetic counselor is recommended</b>.</p><div id="fragilex.T.fragile_x_syndrome_recommende" class="table"><h3><span class="label">Table 6. </span></h3><div class="caption"><p>Fragile X Syndrome: Recommended Evaluations Following Initial Diagnosis</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1384/table/fragilex.T.fragile_x_syndrome_recommende/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fragilex.T.fragile_x_syndrome_recommende_lrgtbl__"><table><thead><tr><th id="hd_h_fragilex.T.fragile_x_syndrome_recommende_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">System/Concern</th><th id="hd_h_fragilex.T.fragile_x_syndrome_recommende_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation</th><th id="hd_h_fragilex.T.fragile_x_syndrome_recommende_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comment</th></tr></thead><tbody><tr><td headers="hd_h_fragilex.T.fragile_x_syndrome_recommende_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Development</b></td><td headers="hd_h_fragilex.T.fragile_x_syndrome_recommende_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Complete developmental &#x00026; educational assessments for educational planning</td><td headers="hd_h_fragilex.T.fragile_x_syndrome_recommende_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Incl motor, adaptive, cognitive, &#x00026; speech/language evaluation</div></li><li class="half_rhythm"><div>Evaluation for early intervention / special education</div></li></ul>
</td></tr><tr><td headers="hd_h_fragilex.T.fragile_x_syndrome_recommende_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Occupational therapy evaluation</td><td headers="hd_h_fragilex.T.fragile_x_syndrome_recommende_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluate fine motor skills, motor planning, sensory issues, self-regulation skills, adaptive functioning, &#x00026; daily life skills.</td></tr><tr><td headers="hd_h_fragilex.T.fragile_x_syndrome_recommende_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Psychiatric/</b><br /><b>Behavioral</b></td><td headers="hd_h_fragilex.T.fragile_x_syndrome_recommende_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comprehensive behavioral &#x00026; neuropsychiatric evaluation</td><td headers="hd_h_fragilex.T.fragile_x_syndrome_recommende_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluate for concentration/attention problems, anxiety, obsessive-compulsive disorder, aggression, depression, &#x00026;/or traits suggestive of autism spectrum disorder.</td></tr><tr><td headers="hd_h_fragilex.T.fragile_x_syndrome_recommende_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Musculoskeletal</b></td><td headers="hd_h_fragilex.T.fragile_x_syndrome_recommende_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Orthopedics / physical medicine &#x00026; rehabilitation / physical therapy evaluation</td><td headers="hd_h_fragilex.T.fragile_x_syndrome_recommende_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluate for joint hyperextensibility, <i>pes planus</i>, scoliosis, &#x00026; hypotonia.</td></tr><tr><td headers="hd_h_fragilex.T.fragile_x_syndrome_recommende_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Neurologic</b></td><td headers="hd_h_fragilex.T.fragile_x_syndrome_recommende_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Neurology evaluation if history of spells that may represent seizures</td><td headers="hd_h_fragilex.T.fragile_x_syndrome_recommende_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluate for seizures.</td></tr><tr><td headers="hd_h_fragilex.T.fragile_x_syndrome_recommende_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Gastrointestinal/</b><br /><b>Feeding</b></td><td headers="hd_h_fragilex.T.fragile_x_syndrome_recommende_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gastroenterology / nutrition / feeding team evaluation if issues are present</td><td headers="hd_h_fragilex.T.fragile_x_syndrome_recommende_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluate for infant feeding issues incl attention to possible gastroesophageal reflux.</td></tr><tr><td headers="hd_h_fragilex.T.fragile_x_syndrome_recommende_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Eyes</b></td><td headers="hd_h_fragilex.T.fragile_x_syndrome_recommende_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ophthalmologic evaluation</td><td headers="hd_h_fragilex.T.fragile_x_syndrome_recommende_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">To assess for strabismus</td></tr><tr><td headers="hd_h_fragilex.T.fragile_x_syndrome_recommende_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Ears/Hearing</b></td><td headers="hd_h_fragilex.T.fragile_x_syndrome_recommende_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Otolaryngology/audiology evaluation</td><td headers="hd_h_fragilex.T.fragile_x_syndrome_recommende_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Assess for evidence of recurrent otitis media &#x00026; associated hearing loss.</td></tr><tr><td headers="hd_h_fragilex.T.fragile_x_syndrome_recommende_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Cardiac</b></td><td headers="hd_h_fragilex.T.fragile_x_syndrome_recommende_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Baseline evaluation w/cardiologist</td><td headers="hd_h_fragilex.T.fragile_x_syndrome_recommende_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Incl echocardiogram for mitral valve prolapse &#x00026; aortic root dilatation</td></tr><tr><td headers="hd_h_fragilex.T.fragile_x_syndrome_recommende_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Sleep</b></td><td headers="hd_h_fragilex.T.fragile_x_syndrome_recommende_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sleep study if sleep issues are present</td><td headers="hd_h_fragilex.T.fragile_x_syndrome_recommende_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluate for sleep apnea.</td></tr></tbody></table></div></div><div id="fragilex.T.fragile_xassociated_tremorata" class="table"><h3><span class="label">Table 7. </span></h3><div class="caption"><p>Fragile X-Associated Tremor/Ataxia Syndrome(FXTAS): Recommended Evaluations Following Initial Diagnosis</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1384/table/fragilex.T.fragile_xassociated_tremorata/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fragilex.T.fragile_xassociated_tremorata_lrgtbl__"><table><thead><tr><th id="hd_h_fragilex.T.fragile_xassociated_tremorata_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">System/Concern</th><th id="hd_h_fragilex.T.fragile_xassociated_tremorata_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation</th><th id="hd_h_fragilex.T.fragile_xassociated_tremorata_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comment</th></tr></thead><tbody><tr><td headers="hd_h_fragilex.T.fragile_xassociated_tremorata_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Neurologic</b></td><td headers="hd_h_fragilex.T.fragile_xassociated_tremorata_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Neurologic evaluation w/movement disorder specialist</td><td headers="hd_h_fragilex.T.fragile_xassociated_tremorata_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_fragilex.T.fragile_xassociated_tremorata_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Motor</b></td><td headers="hd_h_fragilex.T.fragile_xassociated_tremorata_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Physical therapy</td><td headers="hd_h_fragilex.T.fragile_xassociated_tremorata_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Plan should be to maintain gait &#x00026; assist w/optimal support equipment, if needed.</td></tr><tr><td headers="hd_h_fragilex.T.fragile_xassociated_tremorata_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Fine motor</b></td><td headers="hd_h_fragilex.T.fragile_xassociated_tremorata_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Occupational therapy</td><td headers="hd_h_fragilex.T.fragile_xassociated_tremorata_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Manage tremor, work on assisted daily living, &#x00026; obtain adaptive devices, if needed.</td></tr><tr><td headers="hd_h_fragilex.T.fragile_xassociated_tremorata_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Psychiatric/</b><br /><b>Behavioral</b></td><td headers="hd_h_fragilex.T.fragile_xassociated_tremorata_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Neuropsychiatric evaluation</td><td headers="hd_h_fragilex.T.fragile_xassociated_tremorata_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Identify &#x00026; treat any comorbid psychiatric conditions.</td></tr></tbody></table></div></div><div id="fragilex.T.fmr1_primary_ovarian_insuffic" class="table"><h3><span class="label">Table 8. </span></h3><div class="caption"><p><i>FMR1</i> Primary Ovarian Insufficiency (FXPOI): Recommended Evaluations Following Initial Diagnosis</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1384/table/fragilex.T.fmr1_primary_ovarian_insuffic/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fragilex.T.fmr1_primary_ovarian_insuffic_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_fragilex.T.fmr1_primary_ovarian_insuffic_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">System/Concern</th><th id="hd_h_fragilex.T.fmr1_primary_ovarian_insuffic_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation</th><th id="hd_h_fragilex.T.fmr1_primary_ovarian_insuffic_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comment</th></tr></thead><tbody><tr><td headers="hd_h_fragilex.T.fmr1_primary_ovarian_insuffic_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Genitourinary</b></td><td headers="hd_h_fragilex.T.fmr1_primary_ovarian_insuffic_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gynecologic evaluation</td><td headers="hd_h_fragilex.T.fmr1_primary_ovarian_insuffic_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Assess ovarian reserve hormonal markers<br />&#x00026; perform transvaginal ultrasound.</td></tr><tr><td headers="hd_h_fragilex.T.fmr1_primary_ovarian_insuffic_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Psychiatric</b></td><td headers="hd_h_fragilex.T.fmr1_primary_ovarian_insuffic_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Psychological referral</td><td headers="hd_h_fragilex.T.fmr1_primary_ovarian_insuffic_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluate for anxiety &#x00026; depression.</td></tr><tr><td headers="hd_h_fragilex.T.fmr1_primary_ovarian_insuffic_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Skeletal</b></td><td headers="hd_h_fragilex.T.fmr1_primary_ovarian_insuffic_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DEXA scan</td><td headers="hd_h_fragilex.T.fmr1_primary_ovarian_insuffic_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluate for low bone mineral density.</td></tr><tr><td headers="hd_h_fragilex.T.fmr1_primary_ovarian_insuffic_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Endocrine</b></td><td headers="hd_h_fragilex.T.fmr1_primary_ovarian_insuffic_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Thyroid testing</td><td headers="hd_h_fragilex.T.fmr1_primary_ovarian_insuffic_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluate for hypothyroidism.</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">DEXA = dual x-ray absorptiometry</p></div></dd></dl></div></div></div></div><div id="fragilex.Treatment_of_Manifestations__FX"><h3>Treatment of Manifestations &#x02013; FXS</h3><p>No specific treatment is available. Supportive and symptom-based therapy for children and adults with fragile X syndrome (FXS) is currently provided by the Fragile X Clinical and Research Consortium (FXCRC). The National Fragile X Foundation has established and collaborates with the FXCRC, which currently consists of 32 clinics that specialize in FXS, performing evaluations and providing recommendations to local practitioners on management of a child or adult with FXS. The providers at the FXCRC clinics have generated and continue to update FXS treatment guidelines and recommendations (see <a href="https://fragilex.org/our-research/nfxf/treatment-guidelines/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">fragilex.org</a>).</p><p>Treatment is typically a dual approach: psychopharmacologic treatment of symptoms as needed in conjunction with therapeutic services, such as behavioral intervention, speech and language therapy, occupational therapy, and individualized educational support.</p><p>Medications used to treat symptoms in FXS are often the same medications used in the general population. However, individuals with FXS are more sensitive to the adverse effects of psychotropic medications. Thus, these medications should start at low doses and gradually increase to the optimal dosage to avoid adverse effects.</p><p>Early educational intervention, special education, and vocational training should be aimed specifically at the known impediments to learning. Parents and teachers of children with FXS have recognized the need for individual attention, small class size, and the avoidance of sudden change. More specific guidelines are available through education resources (see <a href="#fragilex.Resources">Resources</a>). See also <a href="#fragilex.Developmental_Delay__Intellectu">Developmental Delay / Intellectual Disability Management Issues</a>.</p><p>Routine medical management of strabismus, otitis media, gastroesophageal reflux, cardiac issues, musculoskeletal concerns, and seizures is appropriate.</p><div id="fragilex.Developmental_Delay__Intellectu"><h4>Developmental Delay / Intellectual Disability (DD/ID) Management Issues</h4><p>The following information represents typical management recommendations for individuals with DD/ID in the United States; standard recommendations may vary from country to country. In terms of specific elements to consider in developmental and educational evaluations of individuals with FXS, expert consensus documents written by members of the FXCRC provide general guidelines as well as specific recommendations at each age level from preschool to high school and transition programs. These are posted on the National Fragile X Foundation <a href="https://fragilex.org/our-research/nfxf/treatment-guidelines/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">website</a>.</p><p><b>Ages 0-3 years.</b> Referral to an early intervention program is recommended for access to occupational, physical, speech, and feeding therapy as well as infant mental health services, special educators, and sensory impairment specialists. In the US, early intervention is a federally funded program available in all states and provides in-home services to target individual therapy needs.</p><p><b>Ages 3-5 years.</b> In the US, developmental preschool through the local public school district is recommended. Before placement, an evaluation is made to determine needed services and therapies and an individualized education plan (IEP) is developed for those who qualify based on established motor, language, social, or cognitive delay. The early intervention program typically assists with this transition. Developmental preschool is center based; for children too medically unstable to attend, home-based services are provided.</p><p><b>All ages.</b> Consultation with a developmental pediatrician is recommended to ensure the involvement of appropriate community, state, and educational agencies and to support parents in maximizing quality of life. Some issues to consider:</p><ul><li class="half_rhythm"><div>Individualized education plan (IEP) services:</div><ul><li class="half_rhythm"><div>An IEP provides specially designed instruction and related services for those who qualify.</div></li><li class="half_rhythm"><div>IEP services will be reviewed annually to determine whether any changes are needed.</div></li><li class="half_rhythm"><div>As required by special education law, children should be in the least restrictive environment feasible at school and included in general education as much as possible and when appropriate.</div></li><li class="half_rhythm"><div>Vision and hearing consultants should be a part of the child's IEP team to support access to academic material.</div></li><li class="half_rhythm"><div>PT, OT, and speech services will be provided in the IEP to the extent that the need affects the child's access to academic material. Beyond that, private supportive therapies based on the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual's needs may be considered. Specific recommendations regarding type of therapy can be made by a developmental pediatrician.</div></li><li class="half_rhythm"><div>As a child enters the teen years, a transition plan should be discussed and incorporated in the IEP. For those receiving IEP services, the public school district is required to provide services until age 21.</div></li></ul></li><li class="half_rhythm"><div>A 504 plan (Section 504: a US federal statute that prohibits discrimination based on disability) can be considered for those who require accommodations or modifications such as front-of-class seating, assistive technology devices, classroom scribes, extra time between classes, modified assignments, and enlarged text.</div></li><li class="half_rhythm"><div>Developmental Disabilities Administration (DDA) enrollment is recommended. DDA is a US public agency that provides services and support to qualified individuals. Eligibility differs by state but is typically determined by diagnosis and/or associated cognitive/adaptive disabilities.</div></li><li class="half_rhythm"><div>Families with limited income and resources may also qualify for supplemental security income (SSI) for their child with a disability.</div></li></ul></div><div id="fragilex.Motor_Dysfunction"><h4>Motor Dysfunction</h4><p><b>Gross motor dysfunction</b></p><ul><li class="half_rhythm"><div>Physical therapy is recommended to maximize mobility and to reduce the risk for later-onset orthopedic complications (e.g., contractures, scoliosis, hip dislocation).</div></li><li class="half_rhythm"><div>Consider use of durable medical equipment and positioning devices as needed (e.g., wheelchairs, walkers, bath chairs, orthotics, adaptive strollers).</div></li><li class="half_rhythm"><div>For muscle tone abnormalities including hypertonia or dystonia, consider involving appropriate specialists to aid in management of baclofen, tizanidine, Botox<sup>&#x000ae;</sup>, anti-parkinsonian medications, or orthopedic procedures.</div></li></ul><p><b>Fine motor dysfunction.</b> Occupational therapy is recommended for difficulty with fine motor skills that affect adaptive function such as feeding, grooming, dressing, and writing.</p><p><b>Oral motor dysfunction</b> should be assessed at each visit and clinical feeding evaluations and/or radiographic swallowing studies should be obtained for choking/gagging during feeds, poor weight gain, frequent respiratory illnesses, or feeding refusal that is not otherwise explained. Assuming that the individual is safe to eat by mouth, feeding therapy (typically from an occupational or speech therapist) is recommended to help improve coordination or sensory-related feeding issues. Feeds can be thickened or chilled for safety. When feeding dysfunction is severe, an NG-tube or G-tube may be necessary. Feeding therapy can be helpful to improve coordination or sensory-related feeding issues. A nutritionist or dietician may be helpful in addressing issues such a picky eating and weight concerns.</p><p><b>Communication issues.</b> Consider evaluation for alternative means of communication (e.g., <a href="http://www.asha.org/NJC/AAC/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Augmentative and Alternative Communication</a> [AAC]) if speech is very delayed. An AAC evaluation can be completed by a speech-language pathologist who has expertise in the area. The evaluation will consider cognitive abilities and sensory impairments to determine the most appropriate form of communication. AAC devices can range from low-tech, such as picture exchange communication, to high-tech, such as voice-generating devices. Contrary to popular belief, AAC devices do not hinder verbal development of speech and in many cases, can improve it.</p></div><div id="fragilex.SocialBehavioral_Concerns"><h4>Social/Behavioral Concerns</h4><p><b>Behavior challenges.</b> Management of behavior can involve a multidisciplinary clinical team that includes a psychologist, a clinician to prescribe and manage medication treatment (psychiatrist, neurologist, or developmental pediatrician), occupational therapist, speech language therapist, and behavioral analyst. A functional behavioral assessment (FBA) may be helpful. Children with FXS should be evaluated for autism spectrum disorder (ASD). If they meet clinical criteria for ASD, children may qualify for and benefit from interventions used in treatment of ASD, including applied behavior analysis (ABA). ABA therapy is targeted to the individual child's behavioral, social, and adaptive strengths and weaknesses and is typically performed one on one with a board-certified behavior analyst.</p><p><b>Hyperarousal.</b> An occupational therapist can be helpful to guide the implementation of accommodations to avoid overstimulation as well as provide self-regulation skills to manage hyperarousal in individuals with FXS.</p><p><b>Sensory issues.</b> An occupational therapist can be helpful to identify interventions for sensory issues, which may include desensitization or accommodations.</p><p><b>ADHD.</b> Medications may include psychostimulants (such as methylphenidate- or dextroamphetamine-based medications), atomoxetine (a selective norepinephrine reuptake inhibitor), alpha-agonists, and alternative pharmacologic treatments (folic or folinic acid, L-acetylcarnitine). Medications can be used in conjunction with behavioral therapy and accommodations to avoid distractions.</p><p><b>Aggression and/or self-injurious behavior.</b> Medications can include selective serotonin reuptake inhibitors (SSRIs) if aggression and self-injury are due to anxiety, and antipsychotic medications (risperidone and aripiprazole) if behaviors are severe. Aripriprazole has also been shown to be effective in FXS [<a class="bk_pop" href="#fragilex.REF.erickson.2011.85">Erickson et al 2011</a>, <a class="bk_pop" href="#fragilex.REF.berrykravis.2012.843016">Berry-Kravis et al 2012</a>]. Therapy could also include the recognition of triggers and accommodations to avoid them. In children, a crisis intervention plan can be part of an IEP. For adults, a plan could be applied in the home, work, or community setting.</p><p><b>Irritability.</b> Medication can include SSRIs (if irritability is due to anxiety or perseveration) or antipsychotics such as aripiprazole or risperidone.</p><p><b>Anxiety.</b> Medications can include SSRIs or other medications used to treat anxiety in the general population. Medication should be used in conjunction with behavioral therapy, such as recognition and avoidance of triggers, development of self-regulation and coping skills, accommodations, and cognitive behavioral therapy.</p><p><b>Sleep problems.</b> Management of sleep problems can include behavioral approaches such as the development of a sleep schedule, bedtime routine, and calming strategies. If needed, medication can include melatonin, clonidine, guanfacine, trazodone, and quetiapine.</p></div></div><div id="fragilex.Treatment_of_Manifestations__FX_1"><h3>Treatment of Manifestations &#x02013; FXTAS and FXPOI</h3><div id="fragilex.FXTAS_1"><h4>FXTAS</h4><p>No specific treatment is available. Treatment of FXTAS is currently symptomatic and supportive and should be tailored to the individual. Current recommendations are based on anecdotal evidence in individuals with FXTAS and evidence from disorders that are similar to FXTAS.</p><p>Treatment should be multidisciplinary and include medications; specialty care in neurology and psychiatry; and therapy such as psychological counseling, speech therapy, occupational therapy, physical therapy, and gait training.</p><div id="fragilex.T.treatment_of_manifestations_i" class="table"><h3><span class="label">Table 9. </span></h3><div class="caption"><p>Treatment of Manifestations in Individuals with FXTAS</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1384/table/fragilex.T.treatment_of_manifestations_i/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fragilex.T.treatment_of_manifestations_i_lrgtbl__"><table><thead><tr><th id="hd_h_fragilex.T.treatment_of_manifestations_i_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Manifestation/<br />Concern</th><th id="hd_h_fragilex.T.treatment_of_manifestations_i_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Treatment</th><th id="hd_h_fragilex.T.treatment_of_manifestations_i_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Considerations/Other</th></tr></thead><tbody><tr><td headers="hd_h_fragilex.T.treatment_of_manifestations_i_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Tremor</b></td><td headers="hd_h_fragilex.T.treatment_of_manifestations_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Primidone, &#x003b2;-blockers, or levotriacetam</td><td headers="hd_h_fragilex.T.treatment_of_manifestations_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_fragilex.T.treatment_of_manifestations_i_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Deep brain stimulation may be considered for individuals w/debilitating tremor w/little ataxia or white matter disease.</td><td headers="hd_h_fragilex.T.treatment_of_manifestations_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Has been shown to improve tremor but worsen ataxia &#x00026; speech</td></tr><tr><td headers="hd_h_fragilex.T.treatment_of_manifestations_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Ataxia / Cerebellar dysfunction</b></td><td headers="hd_h_fragilex.T.treatment_of_manifestations_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Medications incl amantadine, buspirone, varenicline, riluzole, or ampyra can be considered.</td><td headers="hd_h_fragilex.T.treatment_of_manifestations_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No evidence for efficacy in FXTAS</td></tr><tr><td headers="hd_h_fragilex.T.treatment_of_manifestations_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Neuropathic pain</b></td><td headers="hd_h_fragilex.T.treatment_of_manifestations_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gabapentin, pregabalin, duloxetine, or topical lidocaine patches</td><td headers="hd_h_fragilex.T.treatment_of_manifestations_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Avoid opioids.</td></tr><tr><td headers="hd_h_fragilex.T.treatment_of_manifestations_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Cognitive decline</b></td><td headers="hd_h_fragilex.T.treatment_of_manifestations_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Supportive treatment only</td><td headers="hd_h_fragilex.T.treatment_of_manifestations_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluate &#x00026; treat for clinical conditions assoc w/cognitive decline that may compound the cognitive decline in FXTAS: vitamin deficiencies (e.g., vitamin D, folate, B<sub>12</sub> deficiencies), thyroid deficiency, hypertension, sleep apnea, &#x00026; psychiatric problems.</td></tr><tr><td headers="hd_h_fragilex.T.treatment_of_manifestations_i_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Depression/</b><br /><b>Anxiety</b></td><td headers="hd_h_fragilex.T.treatment_of_manifestations_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Psychiatric referral</td><td headers="hd_h_fragilex.T.treatment_of_manifestations_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_fragilex.T.treatment_of_manifestations_i_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">SSRIs or selective serotonin-noradrenaline reuptake inhibitors</td><td headers="hd_h_fragilex.T.treatment_of_manifestations_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Individuals should be monitored for balance issues.</td></tr></tbody></table></div></div></div><div id="fragilex.FXPO"><h4>FXPO</h4><p>No specific treatment is available. Gynecologic or reproductive endocrinologic evaluation can provide appropriate treatment and counseling for reproductive considerations and hormone replacement.</p><div id="fragilex.T.treatment_of_manifestations_i_1" class="table"><h3><span class="label">Table 10. </span></h3><div class="caption"><p>Treatment of Manifestations in Individuals with FXPOI</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1384/table/fragilex.T.treatment_of_manifestations_i_1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fragilex.T.treatment_of_manifestations_i_1_lrgtbl__"><table><thead><tr><th id="hd_h_fragilex.T.treatment_of_manifestations_i_1_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Manifestation/Concern</th><th id="hd_h_fragilex.T.treatment_of_manifestations_i_1_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Treatment</th><th id="hd_h_fragilex.T.treatment_of_manifestations_i_1_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Considerations/Other</th></tr></thead><tbody><tr><td headers="hd_h_fragilex.T.treatment_of_manifestations_i_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Infertility</b></td><td headers="hd_h_fragilex.T.treatment_of_manifestations_i_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Referral to gynecologist or reproductive endocrinologist</td><td headers="hd_h_fragilex.T.treatment_of_manifestations_i_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Discuss contraception &#x00026; fertility treatment options incl spontaneous conception, donor oocyte, &#x00026; donor embryo in vitro fertilization.</td></tr><tr><td headers="hd_h_fragilex.T.treatment_of_manifestations_i_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Ovarian insufficiency</b></td><td headers="hd_h_fragilex.T.treatment_of_manifestations_i_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hormone replacement</td><td headers="hd_h_fragilex.T.treatment_of_manifestations_i_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Due to risk of low bone mineral density &#x00026; osteoporosis</td></tr><tr><td headers="hd_h_fragilex.T.treatment_of_manifestations_i_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Depression/Anxiety</b></td><td headers="hd_h_fragilex.T.treatment_of_manifestations_i_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Referral to psychologist</td><td headers="hd_h_fragilex.T.treatment_of_manifestations_i_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div></div><p><b>Reproductive considerations.</b> Some women can have <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> ovulation, which carries an associated chance (or risk) of spontaneous conception. There is currently no fertility treatment available to increase these spontaneous conception rates. Preliminary studies, however, indicate that ethinyl estradiol may be helpful [<a class="bk_pop" href="#fragilex.REF.check.2004.299">Check et al 2004</a>,<a class="bk_pop" href="#fragilex.REF.tartagni.2007.858">Tartagni et al 2007</a>].</p><ul><li class="half_rhythm"><div>Women who are not preventing pregnancy should be referred for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> to discuss the risks of transmission of the <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> or full mutation to a child.</div></li><li class="half_rhythm"><div>If women do not wish to conceive, reliable contraception is necessary. This includes long-acting contraceptives (e.g., intrauterine device or implant), tubal ligation, or vasectomy. Combined contraceptives (e.g., oral contraceptives, vaginal ring) may have a higher failure rate.</div></li><li class="half_rhythm"><div>For women who desire fertility treatment to increase the chance of conception, both donor oocyte and donor embryo in vitro fertilization (IVF) are reasonable options. IVF in women with POI using autologous oocytes has very low success rates.</div></li></ul><p><b>Hormone replacement therapy (HRT).</b> At the time of diagnosis, women with FXPOI are recommended to start HRT and continue until the median age of menopause to decrease development of low bone mineral density / osteoporosis, menopausal symptoms, and earlier cardiovascular disease [<a class="bk_pop" href="#fragilex.REF.north_american_menopause_society.2012.257">North American Menopause Society 2012</a>].</p><ul><li class="half_rhythm"><div>HRT can reverse the negative effects of a hypoestrogenic environment on bone mineral density. It can be administered through many routes, but transdermal estradiol with cyclic progesterone (or a progestin-releasing intrauterine device) mimics physiologic hormone levels.</div></li><li class="half_rhythm"><div>There is evidence from smaller trials that this physiologic replacement is superior to combined contraception for bone mineral density [<a class="bk_pop" href="#fragilex.REF.crofton.2010.707">Crofton et al 2010</a>, <a class="bk_pop" href="#fragilex.REF.cartwright.2016.3497">Cartwright et al 2016</a>]. In addition, a transdermal route minimizes the associated risk for thromboembolism. Women should maintain adequate calcium and vitamin D intake, either through food or sunlight, respectively, or via supplements. Weight-bearing exercises are also recommended.</div></li></ul><p><b>Psychological concerns.</b> The diagnosis of POI and its fertility implications in combination with its associated menopausal symptoms can be very difficult. In addition, women with FXPOI have higher rates of anxiety and depression. Referral for psychological support may be helpful.</p></div></div><div id="fragilex.Surveillance"><h3>Surveillance</h3><div id="fragilex.T.recommended_surveillance_for" class="table"><h3><span class="label">Table 11. </span></h3><div class="caption"><p>Recommended Surveillance for Individuals with Fragile X Syndrome</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1384/table/fragilex.T.recommended_surveillance_for/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fragilex.T.recommended_surveillance_for_lrgtbl__"><table><thead><tr><th id="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">System/Concern</th><th id="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation</th><th id="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Frequency</th></tr></thead><tbody><tr><td headers="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Eyes</b></td><td headers="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comprehensive ophthalmologic exam by age 4 yrs to evaluate for strabismus &#x00026; emergence of farsightedness</td><td headers="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2-yr follow up</td></tr><tr><td headers="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Ears</b></td><td headers="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Visualize tympanic membranes.</td><td headers="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Each visit</td></tr><tr><td headers="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Dental</b></td><td headers="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dental exam</td><td headers="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Annually</td></tr><tr><td headers="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Cardiovascular</b></td><td headers="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Children: assess for murmur or click; if present, refer to cardiologist.</td><td headers="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Each visit</td></tr><tr><td headers="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Adults: clinical exam, ECG, &#x00026; echocardiogram; refer to cardiologist if needed (e.g., if murmur is heard).</td><td headers="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Annually</td></tr><tr><td headers="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Respiratory</b></td><td headers="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Assess for signs of obstructive sleep apnea &#x00026; perform sleep study if needed.</td><td headers="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Each visit</td></tr><tr><td headers="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Gastrointestinal</b></td><td headers="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Assess for symptoms of gastroesophageal reflux disease; refer to GI specialist if needed.</td><td headers="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Each visit</td></tr><tr><td headers="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Musculoskeletal</b></td><td headers="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Children: physical exam at birth; refer to orthopedics, physiotherapy, &#x00026; orthotics if needed.</td><td headers="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Every 4 mos</td></tr><tr><td headers="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Adults: physical exam; refer to orthopedics, physiotherapy if needed.</td><td headers="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Each visit</td></tr><tr><td headers="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Neurologic</b></td><td headers="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Children: assess history for signs of seizures; refer for EEG &#x00026; neurology consult if needed.</td><td headers="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Each visit</td></tr><tr><td headers="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Adults: assess for atypical seizures if suspicious symptoms exist or intellectual function decreases; refer for EEG &#x00026; neurology consult if needed.</td><td headers="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Each visit</td></tr><tr><td headers="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Psychiatric</b></td><td headers="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Adults: assess for anxiety, depression, &#x00026; mood lability. Consider a serotonin agent for severe symptoms.</td><td headers="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Each visit</td></tr></tbody></table></div></div><div id="fragilex.T.recommended_surveillance_for_1" class="table"><h3><span class="label">Table 12. </span></h3><div class="caption"><p>Recommended Surveillance for Individuals with FXTAS</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1384/table/fragilex.T.recommended_surveillance_for_1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fragilex.T.recommended_surveillance_for_1_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">System/Concern</th><th id="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation</th><th id="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Frequency</th></tr></thead><tbody><tr><td headers="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Cardiovascular</b></td><td headers="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Age-appropriate blood pressure &#x00026; cholesterol monitoring</td><td headers="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ongoing aggressive management of CV risk factors recommended, given diffuse white matter injuries in FXTAS.</td></tr><tr><td headers="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Cognition</b></td><td headers="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">MOCA survey&#x000a0;<sup>1</sup></td><td headers="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Annual</td></tr><tr><td headers="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Psychiatric features</b></td><td headers="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Beck Depression<br />Inventory or similar</td><td headers="hd_h_fragilex.T.recommended_surveillance_for_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Annual</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">CV = cardiovascular</p></div></dd><dt>1. </dt><dd><div id="fragilex.TF.12.1"><p class="no_margin">Montreal Cognitive Assessment (MOCA) survey is a screening instrument for mild cognitive impairment.</p></div></dd></dl></div></div></div><div id="fragilex.T.recommended_surveillance_for_2" class="table"><h3><span class="label">Table 13. </span></h3><div class="caption"><p>Recommended Surveillance for Individuals with FXPOI</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1384/table/fragilex.T.recommended_surveillance_for_2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fragilex.T.recommended_surveillance_for_2_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_fragilex.T.recommended_surveillance_for_2_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">System/Concern</th><th id="hd_h_fragilex.T.recommended_surveillance_for_2_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation</th><th id="hd_h_fragilex.T.recommended_surveillance_for_2_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Frequency</th></tr></thead><tbody><tr><td headers="hd_h_fragilex.T.recommended_surveillance_for_2_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Genitourinary</b></td><td headers="hd_h_fragilex.T.recommended_surveillance_for_2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Referral to gynecologist or reproductive endocrinologist for<br />discussion of initiating/continuing HRT &#x00026; fertility options</td><td headers="hd_h_fragilex.T.recommended_surveillance_for_2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Annually</td></tr><tr><td headers="hd_h_fragilex.T.recommended_surveillance_for_2_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Skeletal</b></td><td headers="hd_h_fragilex.T.recommended_surveillance_for_2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DEXA scan (only if history of low bone mineral density on<br />initial evaluation &#x00026;/or not taking adequate HRT)</td><td headers="hd_h_fragilex.T.recommended_surveillance_for_2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Every 2 yrs</td></tr><tr><td headers="hd_h_fragilex.T.recommended_surveillance_for_2_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Psychiatric</b></td><td headers="hd_h_fragilex.T.recommended_surveillance_for_2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Referral to psychologist as needed</td><td headers="hd_h_fragilex.T.recommended_surveillance_for_2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">DEXA = dual x-ray absorptiometry</p></div></dd></dl></div></div></div></div><div id="fragilex.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p><b>FXTAS.</b> Affected individuals should avoid the following:</p><ul><li class="half_rhythm"><div>Typical and atypical antipsychotics with significant anti-dopaminergic effects, which can exacerbate parkinsonism</div></li><li class="half_rhythm"><div>Metoclopramide, which can exacerbate parkinsonism</div></li><li class="half_rhythm"><div>Anticholinergic agents, which can exacerbate cognitive complaints</div></li><li class="half_rhythm"><div>Excessive alcohol, which can increase cerebellar dysfunction and postural instability</div></li><li class="half_rhythm"><div>Agents with known cerebellar toxicity or side effects (use with caution)</div></li></ul><p><b>FXPOI.</b> Affected individuals should avoid tobacco products. Tobacco use decreases ovarian reserve and the age of onset of FXPOI. Women who are smokers have, on average, POI onset five years earlier than nonsmokers [<a class="bk_pop" href="#fragilex.REF.allen.2007.2142">Allen et al 2007</a>].</p></div><div id="fragilex.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#fragilex.Related_Genetic_Counseling_Issu">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="fragilex.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Women with FXPOI who conceive have not been reported to have more pregnancy-related complications [<a class="bk_pop" href="#fragilex.REF.hipp.2016.993">Hipp et al 2016</a>]. If donor oocyte in vitro fertilization is used, these pregnancies in general carry higher risks for hypertensive disorders of pregnancy (e.g., preeclampsia), prematurity, and small-for-gestational-age babies [<a class="bk_pop" href="#fragilex.REF.jeve.2016.1471">Jeve et al 2016</a>].</p></div><div id="fragilex.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>There are multiple ongoing trials of medication for behavior or drugs targeting the underlying neurobiological mechanism of fragile X syndrome (FXS) based on animal model studies. For example:</p><ul><li class="half_rhythm"><div>Metformin is a drug that is widely used to treat type 2 diabetes and has been shown to improve outcomes (including circadian rhythm and memory) in mouse and fly models of FXS [<a class="bk_pop" href="#fragilex.REF.gantois.2017.674">Gantois et al 2017</a>, <a class="bk_pop" href="#fragilex.REF.monyak.2017.1140">Monyak et al 2017</a>]. Several trials are under way in children and adults with FXS to assess the efficacy of metformin on a variety of outcomes, including behavior problems, cognition, language deficits, and obesity/excessive appetite.</div></li><li class="half_rhythm"><div>Mavoglurant targets neural plasticity through negatively regulating mGluR5 signaling that becomes enhanced in the absence of FMRP in FXS. Efficacy is being tested by assessing language outcomes following an intensive language intervention in young children with FXS [<a class="bk_pop" href="#fragilex.REF.gomezmancilla.2014.125">Gomez-Mancilla et al 2014</a>].</div></li></ul><p>Additional interventions under investigation for FXS include behavioral therapies, such as behavior analytic treatment to address disruptive behaviors and social gaze training to improve social gaze and shape social skills.</p><p>Allopregnanolone is a naturally occurring neurosteroid that has shown promise in ameliorating the neuronal impairments of FXTAS in animal models [<a class="bk_pop" href="#fragilex.REF.cao.2012.2923">Cao et al 2012</a>]. Studies in humans are in the early stages [<a class="bk_pop" href="#fragilex.REF.wang.2017.1073">Wang et al 2017</a>, <a class="bk_pop" href="#fragilex.REF.napoli.2019.3702">Napoli et al 2019</a>].</p><p>Search <a href="http://www.clinicaltrials.gov" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="fragilex.Genetic_Counseling"><h2 id="_fragilex_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="fragilex.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p><i>FMR1</i> disorders &#x02013; including fragile X syndrome (FXS), fragile X-associated tremor/ataxia syndrome (FXTAS), and <i>FMR1</i> primary ovarian insufficiency (FXPOI) &#x02013; are inherited in an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> manner.</p></div><div id="fragilex.Risk_to_Family_Members"><h3>Risk to Family Members</h3><div id="fragilex.Parents_of_a_Male_Proband"><h4>Parents of a Male Proband</h4><p><b>Mother</b></p><ul><li class="half_rhythm"><div>If a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has an <i>FMR1</i> full mutation, the mother is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> or full mutation.</div></li><li class="half_rhythm"><div>If a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has a <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a>, the mother is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for an intermediate <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> (~45-54 CGG repeats) or premutation allele.</div></li><li class="half_rhythm"><div>If the mother of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for an <i>FMR1</i> expansion with &#x0003e;54 CGG repeats, she may or may not have associated clinical findings:</div><ul><li class="half_rhythm"><div class="half_rhythm"><b>Premutation (~55-200 CGG repeats).</b> Women with premutations are at risk for FXPOI, FXTAS, and other fragile X-associated disorders.</div><div class="half_rhythm">Note: If the mother of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a>: (1) her father may be <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> for a premutation (i.e., a "transmitting male") and may be at risk for FXTAS or (2) her mother may be heterozygous for an intermediate or premutation <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Full mutation (&#x0003e;200 CGG repeats).</b> Approximately 50% of females who have a full <i>FMR1</i> mutation are intellectually disabled; however, they are usually less severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> than males with a full mutation.</div></li></ul></li></ul><p><b>Father.</b> The father of a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> will not have an <i>FMR1</i> disorder nor will he be <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> for an <i>FMR1</i> CGG expansion; therefore, he does not require further evaluation/testing.</p></div><div id="fragilex.Parents_of_a_Female_Proband"><h4>Parents of a Female Proband</h4><p>A female <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> may have inherited an <i>FMR1</i> expansion from either a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> mother or a father with a <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a>.</p><p>Molecular genetic testing of the father (if the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a>) and the mother is recommended.</p></div><div id="fragilex.Sibs_of_a_Proband"><h4>Sibs of a Proband</h4><p>If the mother of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for an <i>FMR1</i> expansion, the chance of transmitting it in each pregnancy is 50%.</p><p>If the father of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> for a <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> (i.e., a "transmitting male"), he will transmit it to all of his daughters and none of his sons.</p><p>For sibs who inherit an <i>FMR1</i> expansion, the risk for an <i>FMR1</i> disorder depends on their gender, the gender of the transmitting parent, and the size of the expanded <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> in the transmitting parent (see <a class="figpopup" href="/books/NBK1384/table/fragilex.T.risk_for_an_fmr1_disorder_in/?report=objectonly" target="object" rid-figpopup="figfragilexTriskforanfmr1disorderin" rid-ob="figobfragilexTriskforanfmr1disorderin">Table 14</a>).</p><div id="fragilex.T.risk_for_an_fmr1_disorder_in" class="table"><h3><span class="label">Table 14. </span></h3><div class="caption"><p>Risk for an <i>FMR1</i> Disorder in Sibs Who Inherit an <i>FMR1</i> CGG Expansion</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1384/table/fragilex.T.risk_for_an_fmr1_disorder_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fragilex.T.risk_for_an_fmr1_disorder_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_1_1" style="text-align:left;vertical-align:middle;">Transmitting<br />Parent</th><th id="hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_1_2" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Risk to Sibs Who Inherit an <i>FMR1</i> CGG Expansion</th><th id="hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_1_3" style="text-align:left;vertical-align:middle;">Comment</th></tr><tr><th headers="hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_1_2" id="hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Hemizygous&#x000a0;male</th><th headers="hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_1_2" id="hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Heterozygous&#x000a0;female</th></tr></thead><tbody><tr><td headers="hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Mother w/</b><br /><b>intermediate</b><br /><b><a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a></b> (~45-<br />54 CGG<br />repeats)</td><td headers="hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_1_2 hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_2_1 hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_2_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:middle;">If <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> remains &#x0003c; ~55 repeats:<br />not at risk for an <i>FMR1</i> disorder</td><td headers="hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_1_3" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>~16% of maternal transmissions of an intermediate <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> may result in a minor variation (i.e., 1 or 2 CGG repeats) in repeat size.&#x000a0;<sup>1</sup></div></li><li class="half_rhythm"><div>Intermediate alleles of ~50-54 repeats may be more unstable than alleles of &#x0003c;50 repeats.&#x000a0;<sup>2</sup></div></li></ul>
</td></tr><tr><td headers="hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_1_2 hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_2_1 hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_2_2" colspan="2" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">If <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> expands into the <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> range:</td></tr><tr><td headers="hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_1_2 hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_2_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">At risk for FXTAS</td><td headers="hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_1_2 hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">At risk for FXPOI, FXTAS, &#x00026; psychiatric disorders</td></tr><tr><td headers="hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_1_1" rowspan="4" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Mother w/</b><br /><b><a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a></b><br /><b><a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a></b> (~55-<br />200 CGG<br />repeats)</td><td headers="hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_1_2 hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_2_1 hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_2_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:middle;">If <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> remains in the <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> range:</td><td headers="hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_1_3" rowspan="4" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>In general, the risk of a maternal <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> becoming a full mutation on transmission to offspring correlates w/number of CGG repeats in the premutation.&#x000a0;<sup>3,&#x000a0;4</sup></div></li><li class="half_rhythm"><div>For premutations w/&#x0003c;100 repeats, the interruption of the CGG repeats by occasional AGG repeats may help evaluate risk of expansion.</div></li></ul>
</td></tr><tr><td headers="hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_1_2 hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_2_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">At risk for FXTAS</td><td headers="hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_1_2 hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">At risk for FXPOI, FXTAS, &#x00026; psychiatric disorders</td></tr><tr><td headers="hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_1_2 hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_2_1 hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_2_2" colspan="2" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">If <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> expands into the full mutation range:&#x000a0;<sup>5</sup></td></tr><tr><td headers="hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_1_2 hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_2_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Affected w/FXS</td><td headers="hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_1_2 hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~50% risk of ID &#x00026; ~50% likelihood of normal intellect</td></tr><tr><td headers="hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Mother w/</b><br /><b>full-mutation</b><br /><b><a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a></b> (&#x0003e;200<br />CGG repeats)</td><td headers="hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_1_2 hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Affected w/FXS</td><td headers="hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_1_2 hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~50% risk of ID &#x00026; ~50% likelihood of normal intellect&#x000a0;<sup>5</sup></td><td headers="hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Father w/</b><br /><b><a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a></b><br /><b><a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a></b><br />("transmitting<br />male"; ~55-<br />200 CGG<br />repeats)</td><td headers="hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_1_2 hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td><td headers="hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_1_2 hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">At risk for FXPOI, FXTAS, &#x00026; psychiatric disorders</td><td headers="hd_h_fragilex.T.risk_for_an_fmr1_disorder_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Premutations transmitted by the father may result in small &#x02191;s in <a class="def" href="/books/n/gene/glossary/def-item/trinucleotide-repeat/">trinucleotide repeat</a> number, but not in full mutations.</div></li><li class="half_rhythm"><div>Premutations transmitted from father to daughter may often regress slightly in repeat number.</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">FXPOI = fragile X-associated primary ovarian insufficiency; FXS = fragile X syndrome; FXTAS = fragile X-associated tremor/ataxia syndrome; ID = intellectual disability</p></div></dd><dt>1. </dt><dd><div id="fragilex.TF.14.1"><p class="no_margin">Intermediate alleles may infrequently contract by a few repeats, and rarely by sufficiently large number of repeats to be in the normal range [<a class="bk_pop" href="#fragilex.REF.nolin.2011.925">Nolin et al 2011</a>].</p></div></dd><dt>2. </dt><dd><div id="fragilex.TF.14.2"><p class="no_margin"><a class="bk_pop" href="#fragilex.REF.nolin.2011.925">Nolin et al [2011]</a></p></div></dd><dt>3. </dt><dd><div id="fragilex.TF.14.3"><p class="no_margin">Rarely, contraction of <a class="def" href="/books/n/gene/glossary/def-item/trinucleotide-repeat/">trinucleotide repeat</a> number occurs, though this appears to be more frequent in paternal transmissions than maternal transmissions, with the highest frequency of contractions in the 70-90 repeat range [<a class="bk_pop" href="#fragilex.REF.nolin.2015.358">Nolin et al 2015</a>].</p></div></dd><dt>4. </dt><dd><div id="fragilex.TF.14.4"><p class="no_margin"><a class="bk_pop" href="#fragilex.REF.nolin.2011.925">Nolin et al [2011]</a> compared the risk of expanding to a full mutation relative to the size of the <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> (N=95). In some categories, risks were significantly different if the premutation was carried by women with a family history of fragile X. For example, maternal premutation alleles with 70-79 CGG repeats had a 54% risk for expansion if there was a family history of fragile X vs an 18% risk in the absence of a family history. Risk of expansion is also increased with fewer AGG <a class="def" href="/books/n/gene/glossary/def-item/trinucleotide-repeat/">trinucleotide repeat</a> interruptions [<a class="bk_pop" href="#fragilex.REF.nolin.2015.358">Nolin et al 2015</a>].</p></div></dd><dt>5. </dt><dd><div id="fragilex.TF.14.5"><p class="no_margin">The physical and behavioral features seen in males with fragile X syndrome have been reported in females <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for the full mutation, but with lower frequency and milder involvement.</p></div></dd></dl></div></div></div></div><div id="fragilex.Offspring_of_an_Individual_with"><h4>Offspring of an Individual with a Premutation</h4><p><b>Males</b> who are <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> for a <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> are considered "transmitting males." The premutation is inherited by all of their daughters and none of their sons. When premutations are transmitted by the father, small increases in <a class="def" href="/books/n/gene/glossary/def-item/trinucleotide-repeat/">trinucleotide repeat</a> number may occur but do not result in full mutations. All daughters of transmitting males are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a premutation and at risk for FXTAS, FXPOI, and other fragile X-associated disorders.</p><p><b>Females</b> who are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> have a 50% risk of transmitting an abnormal (premutation or full-mutation) <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> in each pregnancy.</p></div><div id="fragilex.Offspring_of_an_Individual_with_1"><h4>Offspring of an Individual with a Full Mutation</h4><p><b>Males</b> with a full mutation have intellectual disability and generally do not reproduce.</p><p><b>Females</b> who inherit the full mutation are at an approximately 50% risk for intellectual disability. Whether or not a female has phenotypic manifestations, her offspring are at a 50% risk of inheriting the full mutation.</p></div><div id="fragilex.Other_Family_Members"><h4>Other Family Members</h4><p>The maternal aunts (and their offspring) of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with fragile X syndrome may be at risk of being heterozygotes or being <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> (depending on their gender and family relationship).</p></div><div id="fragilex.PopulationBased_Fragile_X_Syndr"><h4>Population-Based Fragile X Syndrome Screening</h4><p>Newborn screening for FXS has been piloted, but is not currently standard practice [<a class="bk_pop" href="#fragilex.REF.bailey.2017.s216">Bailey et al 2017</a>].</p></div></div><div id="fragilex.Related_Genetic_Counseling_Issu"><h3>Related Genetic Counseling Issues</h3><p><b>Family history.</b> The presence of individuals with premutations within families leads to pedigrees with generation-skipping or seemingly spontaneous occurrences of fragile X syndrome with no previous family history of the disorder.</p><p><b>Grandchildren of transmitting males.</b> The daughters of transmitting males are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a>; thus, their offspring are at risk for fragile X syndrome.</p><p><b>Early diagnosis of fragile X syndrome.</b> The first indication of fragile X syndrome within a family is usually the diagnosis in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child. A survey to assess the timing of a diagnosis in an affected child and <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> for the family indicated that in approximately half of the families surveyed, the diagnosis was made more than a year after the child's development or behavior first raised concerns. Half of the surveyed families reported having subsequent pregnancies before diagnosis of the first affected child. These findings emphasize the importance of increased opportunities for early diagnosis so that children and families can receive all possible benefits, including genetic counseling and intervention services [<a class="bk_pop" href="#fragilex.REF.centers_for_disease_control_and_prevention_cdc_.2002.740">Centers for Disease Control and Prevention 2002</a>].</p><p><b>Fragile X-associated tremor/ataxia syndrome (FXTAS) in males with <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> alleles.</b> When a child is diagnosed with fragile X syndrome and his mother is found to have a premutation <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>, his maternal grandfather is then known to be at risk of developing FXTAS. Females who are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a premutation are also at increased risk for neurologic and psychiatric problems [<a class="bk_pop" href="#fragilex.REF.chonchaiya.2010.38">Chonchaiya et al 2010</a>].</p><p><b>Fragile X-associated primary ovarian insufficiency (FXPOI) in females with <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> alleles.</b> The increased risk for FXPOI (i.e., ovarian insufficiency before age 40 years) in females with premutations should be taken into account when providing <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a>.</p><p>Note: The diagnosis of FXPOI does not eliminate the possibility of subsequent conception. There are reports of women who carry a <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> having a child with fragile X syndrome after being diagnosed with FXPOI [<a class="bk_pop" href="#fragilex.REF.corrigan.2005.1508">Corrigan et al 2005</a>, <a class="bk_pop" href="#fragilex.REF.nelson.2005.1327">Nelson et al 2005</a>].</p><p>For additional information regarding <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> and cascade testing see <a class="bk_pop" href="#fragilex.REF.finucane.2012.752">Finucane et al [2012]</a>.</p><p><b>Gamete donation.</b> Transmission of a fragile X <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> has occurred via sperm donation [<a class="bk_pop" href="#fragilex.REF.wirojanan.2008.888">Wirojanan et al 2008</a>]. Many oocyte and sperm donors from anonymous banks are now screened for <i>FMR1</i> expansions with extended <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> screening.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of genetic status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are known to have an <i>FMR1</i> expansion or who are at risk of having an <i>FMR1</i> expansion.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="fragilex.Prenatal_Testing_and_Preimplant"><h3>Prenatal Testing and Preimplantation Genetic Testing</h3><p>Once an expanded (or altered) <i>FMR1</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> has been identified in a family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-testing/">preimplantation genetic testing</a> (PGT) are possible.</p><div id="fragilex.Preimplantation_Genetic_Testing"><h4>Preimplantation Genetic Testing</h4><p>If a woman with an <i>FMR1</i> expansion chooses to proceed with PGT, she must undergo in vitro fertilization (IVF) with gonadotropin stimulation for ovarian stimulation. Women with FXPOI have extremely low or absent ovarian reserve, and oocyte recruitment to obtain the necessary accumulation of embryos for biopsy and testing is very difficult. One case report of a woman with a FSH level of 33 IU/L delivered an unaffected child after undergoing 20 separate oocyte retrievals to accumulate 15 embryos for biopsy [<a class="bk_pop" href="#fragilex.REF.nayot.2013.1439">Nayot et al 2013</a>].</p><p>Women who are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> who do not have primary ovarian insufficiency have better success rates. However, they tend to need higher gonadotropin stimulation with fewer oocytes retrieved than unaffected women [<a class="bk_pop" href="#fragilex.REF.avraham.2017.1508">Avraham et al 2017</a>]. There is a correlation of higher levels of <i>FMR1</i> <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> in granulosa cells with lower oocyte yield [<a class="bk_pop" href="#fragilex.REF.elizur.2014.e105121">Elizur et al 2014</a>]. Women with mid-range CGG repeats (e.g., 70-100) also have lower oocyte and embryo yields even excluding those with FXPOI [<a class="bk_pop" href="#fragilex.REF.bibi.2010.869">Bibi et al 2010</a>]. This results in a lower number of embryos available for PGT with higher cancellation rates [<a class="bk_pop" href="#fragilex.REF.fern_ndez.2015.965839">Fern&#x000e1;ndez et al 2015</a>].</p></div><div id="fragilex.Interpretation_of_Preimplantati"><h4>Interpretation of Preimplantation and Prenatal Genetic Test Results</h4><p>Importantly, PGT cannot currently be used in clinical practice to determine if a <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> has expanded into the full mutation range, though there are research initiatives in progress to reliably determine repeat expansion from an embryo biopsy [<a class="bk_pop" href="#fragilex.REF.rajanbabu.2017.e10">Rajan-Babu et al 2017</a>].</p><p>In addition, PGT is considered a screening test. The trophectoderm layer, which is biopsied for the testing, is at risk of <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a> [<a class="bk_pop" href="#fragilex.REF.capalbo.2017.492">Capalbo et al 2017</a>] and discordance from the inner cell mass [<a class="bk_pop" href="#fragilex.REF.lawrenz.2019.998">Lawrenz et al 2019</a>]. If a couple chooses to transfer an embryo with the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>, they should be offered early prenatal screening with chorionic villus sampling (CVS) or amniocentesis.</p><p>CVS can be used for prenatal testing to determine the presence of a <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> or full mutation during pregnancy. Follow-up amniocentesis may be needed to confirm the <a class="def" href="/books/n/gene/glossary/def-item/methylation/">methylation</a> status of a full-mutation <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>, given that the methylation status of <i>FMR1</i> is not established in placental tissue until 10-12 weeks' gestation [<a class="bk_pop" href="#fragilex.REF.finucane.2012.752">Finucane et al 2012</a>]. Information regarding fetal sex can be obtained prenatally as well, which may be helpful since female fetuses with an expanded full mutation typically have a less severe <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> [<a class="bk_pop" href="#fragilex.REF.guti_rrez.2013.e1">Guti&#x000e9;rrez et al 2013</a>].</p><p>Full phenotypic information for fetuses diagnosed prenatally with a <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> is difficult to determine, given the <a class="def" href="/books/n/gene/glossary/def-item/variable-expressivity/">variable expressivity</a> of FXPOI and FXTAS. The same unknowns are present when a female fetus is found to have a full mutation, given the variable <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> [<a class="bk_pop" href="#fragilex.REF.finucane.2017.37">Finucane et al 2017</a>]. Families should have pretest counseling regarding these potential results and the inherent unknowns prior to undergoing the invasive prenatal procedures.</p></div></div></div><div id="fragilex.Resources"><h2 id="_fragilex_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>FRAXA Research Foundation</b></div><div>45 Pleasant Street</div><div>Newburyport MA 01950</div><div><b>Phone:</b> 978-462-1866</div><div><b>Fax:</b> 978-463-9985</div><div><b>Email:</b> info@fraxa.org</div><div><a href="http://www.fraxa.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.fraxa.org</a></div></li><li class="half_rhythm"><div><b>My46 Trait Profile</b></div><div><a href="https://www.my46.org/trait-document?trait=Fragile%20X%20syndrome&#x00026;parent=Genetic%20Syndromes&#x00026;type=profile" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Fragile X syndrome</a></div></li><li class="half_rhythm"><div><b>My46 Trait Profile</b></div><div><a href="https://www.my46.org/trait-document?trait=Fragile%20X-associated%20premature%20ovarian%20insufficiency&#x00026;parent=Genetic%20Syndromes&#x00026;type=profile" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Fragile X-associated premature ovarian insufficiency</a></div></li><li class="half_rhythm"><div><b>My46 Trait Profile</b></div><div><a href="https://www.my46.org/trait-document?trait=Fragile%20X-associated%20tremor/ataxia%20syndrome&#x00026;parent=Genetic%20Syndromes&#x00026;type=profile" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Fragile X-associated tremor/ataxia syndrome</a></div></li><li class="half_rhythm"><div><b>National Fragile X Foundation</b></div><div><i>Journal: The Foundation Quarterly. Subscriptions through National Fragile X Foundation</i></div><div>PO Box 190488</div><div>San Francisco CA 94119-0488</div><div><b>Phone:</b> 800-688-8765; 925-938-9300</div><div><b>Fax:</b> 925-938-9315</div><div><b>Email:</b> NATLFX@FragileX.org</div><div><a href="http://www.FragileX.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.FragileX.org</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition=fragilexsyndrome;jsessionid=BEAF9067184121042AD911BFE139A57C" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Fragile X syndrome</a></div></li><li class="half_rhythm"><div><b>NCBI Genes and Disease</b></div><div><a href="/books/NBK22189/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Fragile X syndrome</a></div></li><li class="half_rhythm"><div><b>National Ataxia Foundation</b></div><div>2600 Fernbrook Lane</div><div>Suite 119</div><div>Minneapolis MN 55447</div><div><b>Phone:</b> 763-553-0020</div><div><b>Email:</b> naf@ataxia.org</div><div><a href="http://www.ataxia.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ataxia.org</a></div></li><li class="half_rhythm"><div><b>Fragile X Research Registry</b></div><div>University of North Carolina at Chapel Hill</div><div>Campus Box 3366</div><div>Chapel Hill NC 27599</div><div><b>Phone:</b> 866-744-7879 (toll-free)</div><div><b>Fax:</b> 919-966-7080</div><div><b>Email:</b> info@fragilexregistry.org</div><div><a href="http://www.fragilexregistry.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Fragile X Research Registry</a></div></li></ul></div><div id="fragilex.Molecular_Genetics"><h2 id="_fragilex_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="fragilex.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>FMR1 Disorders: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1384/table/fragilex.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fragilex.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_fragilex.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_fragilex.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_fragilex.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_fragilex.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_fragilex.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_fragilex.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_fragilex.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/2332" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>FMR1</i></a></td><td headers="hd_b_fragilex.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=2332" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Xq27<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_fragilex.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q06787" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Synaptic functional regulator FMR1</a></td><td headers="hd_b_fragilex.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/FMR1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FMR1 @ LOVD</a></td><td headers="hd_b_fragilex.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=FMR1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FMR1</a></td><td headers="hd_b_fragilex.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=FMR1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FMR1</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="fragilex.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="fragilex.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for FMR1 Disorders (<a href="/omim/300623,300624,309550" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1384/table/fragilex.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fragilex.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/300623" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">300623</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FRAGILE X TREMOR/ATAXIA SYNDROME; FXTAS</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/300624" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">300624</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FRAGILE X SYNDROME; FXS</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/309550" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">309550</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FMRP TRANSLATIONAL REGULATOR 1; FMR1</td></tr></tbody></table></div></div><div id="fragilex.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p>Full-mutation alleles are associated with aberrant hypermethylation of the CGG expansion resulting in decrease or silencing of <i>FMR1</i> transcription and loss of FMRP, the protein encoded by the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>. FMRP is found in the cytoplasm of many cell types, including neurons. The protein contains two KH-binding domains found in other proteins with RNA-binding properties and functions as an RNA-binding protein that interacts with a subset of mRNAs containing G-quartet motifs. FMRP is involved in neuronal synapse plasticity by regulating translation of proteins involved in the maintenance and regulation of synapses [<a class="bk_pop" href="#fragilex.REF.santoro.2012.219">Santoro et al 2012</a>]. Absence of FMRP appears to disrupt neurotransmission mediated by the metabotropic glutamate receptor (mGluR) [<a class="bk_pop" href="#fragilex.REF.bear.2004.370">Bear et al 2004</a>].</p><p>Premutation alleles are not associated with hypermethylation but are associated with increased <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> levels. The pathogenic mechanism behind <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a>-associated outcomes (FXTAS, FXPOI, and other fragile X-associated outcomes) is thought to be due to toxicity from elevated levels of <i>FMR1</i> mRNA [<a class="bk_pop" href="#fragilex.REF.galloway.2009.785">Galloway &#x00026; Nelson 2009</a>, <a class="bk_pop" href="#fragilex.REF.tassone.2012.100">Tassone et al 2012</a>]. FMRP levels also decrease in the upper premutation range [<a class="bk_pop" href="#fragilex.REF.hessl.2011.859">Hessl et al 2011</a>].</p><p><b>Mechanism of disease causation.</b> Full-mutation alleles are associated with a <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> mechanism due to aberrant hypermethylation, while the pathogenic mechanisms of the <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> are not well understood but are hypothesized to be due to a <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> toxicity of elevated levels of <i>FMR1</i> <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> [<a class="bk_pop" href="#fragilex.REF.hagerman.2011.211">Hagerman et al 2011</a>].</p><p><b><i>FMR1</i>-specific laboratory technical considerations.</b> Nearly all <i>FMR1</i> pathogenic variants (&#x0003e;99%) resulting in FXS occur as expansions of greater than 200 CGG repeats (full-mutation alleles) in the 5' UTR of <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 1 in <i>FMR1</i>. Deletions and single-nucleotide variants in <i>FMR1</i> account for the remaining pathogenic variants found in individuals with FXS. Premutation alleles range from 55 to 200 CGG repeats.</p></div></div><div id="fragilex.References"><h2 id="_fragilex_References_">References</h2><div id="fragilex.Published_Guidelines__Consensus"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.biancalana.2015.417">Biancalana V, Glaeser D, McQuaid S, Steinbach P. EMQN best practice guidelines for the molecular genetic testing and reporting of fragile X syndrome and other fragile X-associated disorders. <span><span class="ref-journal">Eur J Hum Genet. </span>2015;<span class="ref-vol">23</span>:417–25.</span> [<a href="/pmc/articles/PMC4666582/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4666582</span></a>] [<a href="/pubmed/25227148" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25227148</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.chitayat.2008.837">Chitayat D, Wyatt PR, et al.  Fragile X testing in obstetrics and gynaecology in Canada. <span><span class="ref-journal">J Obstet Gynaecol Can. </span>2008;<span class="ref-vol">30</span>:837–41.</span> [<a href="/pubmed/18845054" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18845054</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.committee_on_genetics.2017.e41">Committee on Genetics.  Committee opinion no. 691: carrier screening for genetic conditions. <span><span class="ref-journal">Obstet Gynecol. </span>2017;<span class="ref-vol">129</span>:e41–55.</span> [<a href="/pubmed/28225426" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28225426</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.finucane.2012.752">Finucane B, Abrams L, Cronister A, Archibald AD, Bennett RL, McConkie-Rosell A. Genetic counseling and testing for FMR1 gene mutations: practice guidelines of the national society of genetic counselors. <span><span class="ref-journal">J Genet Couns. </span>2012;<span class="ref-vol">21</span>:752–60.</span> [<a href="/pubmed/22797890" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22797890</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.hersh.2011.994">Hersh JH, Saul RA., Committee on Genetics.  Health supervision for children with fragile X syndrome. <span><span class="ref-journal">Pediatrics. </span>2011;<span class="ref-vol">127</span>:994–1006.</span> [<a href="/pubmed/21518720" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21518720</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.moeschler.2014.e903">Moeschler JB, Shevell M, et al.  Comprehensive evaluation of the child with intellectual disability or global developmental delays. <span><span class="ref-journal">Pediatrics. </span>2014;<span class="ref-vol">134</span>:e903–18.</span> [<a href="/pubmed/25157020" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25157020</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.monaghan.2013.575">Monaghan KG, Lyon E, Spector EB. ACMG standards and guidelines for fragile X testing: a revision to the disease-specific supplements to the Standards and Guidelines for Clinical Genetics Laboratories of the American College of Medical Genetics and Genomics. <span><span class="ref-journal">Genet Med. </span>2013;<span class="ref-vol">15</span>:575–86.</span> [<a href="/pubmed/23765048" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23765048</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF8">National Fragile X Foundation. Consensus documents on treatments and interventions for fragile X. Available <a href="https://fragilex.org/our-research/nfxf/treatment-guidelines/" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. Accessed 11-14-19.</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.schaefer.2013.399">Schaefer GB, Mendelsohn NJ, et al.  Clinical genetics evaluation in identifying the etiology of autism spectrum disorders: 2013 guideline revisions. <span><span class="ref-journal">Genet Med. </span>2013;<span class="ref-vol">15</span>:399–407.</span> [<a href="/pubmed/23519317" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23519317</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.sherman.2005.584">Sherman S, Pletcher BA, Driscoll DA. Fragile X syndrome: diagnostic and carrier testing. <span><span class="ref-journal">Genet Med. </span>2005;<span class="ref-vol">7</span>:584–7.</span> [<a href="/pmc/articles/PMC3110946/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3110946</span></a>] [<a href="/pubmed/16247297" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16247297</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.sherman.2000.189">Sherman SL. Premature ovarian failure in the fragile X syndrome. <span><span class="ref-journal">Am J Med Genet. </span>2000;<span class="ref-vol">97</span>:189–94.</span> [<a href="/pubmed/11449487" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11449487</span></a>]</div></li></ul></div><div id="fragilex.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.allen.2018.292">Allen EG, Glicksman A, Tortora N, Charen K, He W, Amin A, Hipp H, Shubeck L, Nolin SL, Sherman SL. FXPOI: pattern of AGG interruptions does not show an association with age at amenorrhea among women with a premutation. <span><span class="ref-journal">Front Genet. </span>2018;<span class="ref-vol">9</span>:292.</span> [<a href="/pmc/articles/PMC6086008/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6086008</span></a>] [<a href="/pubmed/30123240" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30123240</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.allen.2005.435">Allen EG, Sherman S, Abramowitz A, Leslie M, Novak G, Rusin M, Scott E, Letz R. Examination of the effect of the polymorphic CGG repeat in the FMR1 gene on cognitive performance. <span><span class="ref-journal">Behav Genet. </span>2005;<span class="ref-vol">35</span>:435–45.</span> [<a href="/pubmed/15971024" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15971024</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.allen.2007.2142">Allen EG, Sullivan AK, Marcus M, Small C, Dominguez C, Epstein MP, Charen K, He W, Taylor KC, Sherman SL. Examination of reproductive aging milestones among women who carry the FMR1 premutation. <span><span class="ref-journal">Hum Reprod. </span>2007;<span class="ref-vol">22</span>:2142–52.</span> [<a href="/pubmed/17588953" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17588953</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.avraham.2017.1508">Avraham S, Almog B, Reches A, Zakar L, Malcov M, Sokolov A, Alpern S, Azem F. The ovarian response in fragile X patients and premutation carriers undergoing IVF-PGD: reappraisal. <span><span class="ref-journal">Hum Reprod. </span>2017;<span class="ref-vol">32</span>:1508–11.</span> [<a href="/pubmed/28472405" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28472405</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.bailey.2017.s216">Bailey DB Jr, Berry-Kravis E, Gane LW, Guarda S, Hagerman R, Powell CM, Tassone F, Wheeler A. Fragile X newborn screening: lessons learned from a multisite screening study. <span><span class="ref-journal">Pediatrics. </span>2017;<span class="ref-vol">139</span>:S216–25.</span> [<a href="/pubmed/28814542" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28814542</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.bailey.2008.2060">Bailey DB Jr, Raspa M, Olmsted M, Holiday DB. Co-occurring conditions associated with FMR1 gene variations: findings from a national parent survey. <span><span class="ref-journal">Am J Med Genet A. </span>2008;<span class="ref-vol">146A</span>:2060–9.</span> [<a href="/pubmed/18570292" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18570292</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.bartholomay.2019">Bartholomay KL, Lee CH, Bruno JL, Lightbody AA, Reiss AL. Closing the gender gap in fragile X syndrome: review on females with FXS and preliminary research findings. <span><span class="ref-journal">Brain Sci. </span>2019;<span class="ref-vol">9</span>(1)</span> [<a href="/pmc/articles/PMC6356553/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6356553</span></a>] [<a href="/pubmed/30642066" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30642066</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.bear.2004.370">Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. <span><span class="ref-journal">Trends Neurosci. </span>2004;<span class="ref-vol">27</span>:370–7.</span> [<a href="/pubmed/15219735" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15219735</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.bennett.2010.1335">Bennett CE, Conway GS, Macperson JN, Jacobs PA, Murray A. Intermediate sized CGG repeats are not a common cause of idiopathic premature ovarian failure. <span><span class="ref-journal">Hum Reprod. </span>2010;<span class="ref-vol">25</span>:1335–8.</span> [<a href="/pmc/articles/PMC2854048/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2854048</span></a>] [<a href="/pubmed/20228389" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20228389</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.berrykravis.2007.2018">Berry-Kravis E, Abrams L, Coffey SM, Hall DA, Greco C, Gane LW, Grigsby J, Bourgeois JA, Finucane B, Jacquemont S, Brunberg JA, Zhang L, Lin J, Tassone F, Hagerman PJ, Hagerman RJ, Leehey MA. Fragile X-associated tremor/ataxia syndrome: clinical features, genetics, and testing guidelines. <span><span class="ref-journal">Mov Disord. </span>2007;<span class="ref-vol">22</span>:2018–30.</span> [<a href="/pubmed/17618523" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17618523</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.berrykravis.2012.843016">Berry-Kravis E, Sumis A, Hervey C, Mathur S. Clinic-based retrospective analysis of psychopharmacology for behavior in fragile X syndrome. <span><span class="ref-journal">Int J Pediatr. </span>2012;<span class="ref-vol">2012</span>:843016</span> [<a href="/pmc/articles/PMC3413981/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3413981</span></a>] [<a href="/pubmed/22899942" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22899942</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.biancalana.2005.962">Biancalana V, Toft M, Le Ber I, Tison F, Scherrer E, Thibodeau S, Mandel JL, Brice A, Farrer MJ, Durr A. FMR1 premutations associated with fragile X-associated tremor/ataxia syndrome in multiple system atrophy. <span><span class="ref-journal">Arch Neurol. </span>2005;<span class="ref-vol">62</span>:962–6.</span> [<a href="/pubmed/15956167" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15956167</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.bibi.2010.869">Bibi G, Malcov M, Yuval Y, Reches A, Ben-Yosef D, Almog B, Amit A, Azem F. The effect of CGG repeat number on ovarian response among fragile X premutation carriers undergoing preimplantation genetic diagnosis. <span><span class="ref-journal">Fertil Steril. </span>2010;<span class="ref-vol">94</span>:869–74.</span> [<a href="/pubmed/19481741" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19481741</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.bodega.2006.952">Bodega B, Bione S, Dalpra L, Toniolo D, Ornaghi F, Vegetti W, Ginelli E, Marozzi A. Influence of intermediate and uninterrupted FMR1 CGG expansions in premature ovarian failure manifestation. <span><span class="ref-journal">Hum Reprod. </span>2006;<span class="ref-vol">21</span>:952–7.</span> [<a href="/pubmed/16361284" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16361284</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.bourgeois.2016.913">Bourgeois JA. Neuropsychiatry of fragile X-premutation carriers with and without fragile X-associated tremor-ataxia syndrome: implications for neuropsychology. <span><span class="ref-journal">Clin Neuropsychol. </span>2016;<span class="ref-vol">30</span>:913–28.</span> [<a href="/pubmed/27355575" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27355575</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.bourgeois.2009.852">Bourgeois JA, Coffey SM, Rivera SM, Hessl D, Gane LW, Tassone F, Greco C, Finucane B, Nelson L, Berry-Kravis E, Grigsby J, Hagerman PJ, Hagerman RJ. A review of fragile X premutation disorders: expanding the psychiatric perspective. <span><span class="ref-journal">J Clin Psychiatry. </span>2009;<span class="ref-vol">70</span>:852–62.</span> [<a href="/pmc/articles/PMC2705685/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2705685</span></a>] [<a href="/pubmed/19422761" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19422761</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.bretherick.2005.376">Bretherick KL, Fluker MR, Robinson WP. FMR1 repeat sizes in the gray zone and high end of the normal range are associated with premature ovarian failure. <span><span class="ref-journal">Hum Genet. </span>2005;<span class="ref-vol">117</span>:376–82.</span> [<a href="/pubmed/16078053" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16078053</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.brussino.2005.145">Brussino A, Gellera C, Saluto A, Mariotti C, Arduino C, Castellotti B, Camerlingo M, de Angelis V, Orsi L, Tosca P, Migone N, Taroni F, Brusco A. FMR1 gene premutation is a frequent genetic cause of late-onset sporadic cerebellar ataxia. <span><span class="ref-journal">Neurology. </span>2005;<span class="ref-vol">64</span>:145–7.</span> [<a href="/pubmed/15642922" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15642922</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.cao.2012.2923">Cao Z, Hulsizer S, Tassone F, Tang HT, Hagerman RJ, Rogawski MA, Hagerman PJ, Pessah IN. Clustered burst firing in FMR1 premutation hippocampal neurons: amelioration with allopregnanolone. <span><span class="ref-journal">Hum Mol Genet. </span>2012;<span class="ref-vol">21</span>:2923–35.</span> [<a href="/pmc/articles/PMC3373240/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3373240</span></a>] [<a href="/pubmed/22466801" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22466801</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.capalbo.2017.492">Capalbo A, Ubaldi FM, Rienzi L, Scott R, Treff N. Detecting mosaicism in trophectoderm biopsies: current challenges and future possibilities. <span><span class="ref-journal">Hum Reprod. </span>2017;<span class="ref-vol">32</span>:492–8.</span> [<a href="/pmc/articles/PMC5400043/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5400043</span></a>] [<a href="/pubmed/27738115" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27738115</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.cartwright.2016.3497">Cartwright B, Robinson J, Seed PT, Fogelman I, Rymer J. Hormone replacement therapy versus the combined oral contraceptive pill in premature ovarian failure: a randomized controlled trial of the effects on bone mineral density. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2016;<span class="ref-vol">101</span>:3497–505.</span> [<a href="/pubmed/27340881" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27340881</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.cellini.2006.1135">Cellini E, Forleo P, Ginestroni A, Nacmias B, Tedde A, Bagnoli S, Mascalchi M, Sorbi S, Piacentini S. Fragile X premutation with atypical symptoms at onset. <span><span class="ref-journal">Arch Neurol. </span>2006;<span class="ref-vol">63</span>:1135–8.</span> [<a href="/pubmed/16908740" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16908740</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.centers_for_disease_control_and_prevention_cdc_.2002.740">Centers for Disease Control and Prevention (CDC).  Delayed diagnosis of fragile X syndrome--United States, 1990-1999. <span><span class="ref-journal">MMWR Morb Mortal Wkly Rep. </span>2002;<span class="ref-vol">51</span>:740–2.</span> [<a href="/pubmed/12201607" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12201607</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.check.2004.299">Check ML, Check JH, Kaplan H. Pregnancy despite imminent ovarian failure and extremely high endogenous gonadotropins and therapeutic strategies: case report and review. <span><span class="ref-journal">Clin Exp Obstet Gynecol. </span>2004;<span class="ref-vol">31</span>:299–301.</span> [<a href="/pubmed/15672973" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15672973</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.chen.2010.589">Chen L, Hadd A, Sah S, Filipovic-Sadic S, Krosting J, Sekinger E, Pan R, Hagerman PJ, Stenzel TT, Tassone F, Latham GJ. An information-rich CGG repeat primed PCR that detects the full range of fragile X expanded alleles and minimizes the need for Southern blot analysis. <span><span class="ref-journal">J Mol Diagn. </span>2010;<span class="ref-vol">12</span>:589–600.</span> [<a href="/pmc/articles/PMC2928422/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2928422</span></a>] [<a href="/pubmed/20616364" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20616364</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.chen.2011.528">Chen L, Hadd A, Sah S, Houghton J, Filipovic-Sadic S, Zhang W, Hagerman PJ, Tassone F, Latham GJ. High-resolution methylation polymerase chain reaction for fragile X analysis: evidence for novel <em>FMR1</em> methylation patterns undetected in Southern blot analyses. <span><span class="ref-journal">Genet Med. </span>2011;<span class="ref-vol">13</span>:528–38.</span> [<a href="/pmc/articles/PMC4043840/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4043840</span></a>] [<a href="/pubmed/21430544" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21430544</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.chonchaiya.2010.38">Chonchaiya W, Nguyen DV, Au J, Campos L, Berry-Kravis EM, Lohse K, Mu Y, Utari A, Hervey C, Wang L, Sorensen P, Cook K, Gane L, Tassone F, Hagerman RJ. Clinical involvement in daughters of men with fragile X-associated tremor ataxia syndrome. <span><span class="ref-journal">Clin Genet. </span>2010;<span class="ref-vol">78</span>:38–46.</span> [<a href="/pmc/articles/PMC4031089/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4031089</span></a>] [<a href="/pubmed/20497189" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20497189</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.coffee.2009.503">Coffee B, Keith K, Albizua I, Malone T, Mowrey J, Sherman SL, Warren ST. Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA. <span><span class="ref-journal">Am J Hum Genet. </span>2009;<span class="ref-vol">85</span>:503–14.</span> [<a href="/pmc/articles/PMC2756550/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2756550</span></a>] [<a href="/pubmed/19804849" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19804849</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.corrigan.2005.1508">Corrigan EC, Raygada MJ, Vanderhoof VH, Nelson LM. A woman with spontaneous premature ovarian failure gives birth to a child with fragile X syndrome. <span><span class="ref-journal">Fertil Steril. </span>2005;<span class="ref-vol">84</span>:1508.</span> [<a href="/pubmed/16275254" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16275254</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.crofton.2010.707">Crofton PM, Evans N, Bath LE, Warner P, Whitehead TJ, Critchley HO, Kelnar CJ, Wallace WH. Physiological versus standard sex steroid replacement in young women with premature ovarian failure: effects on bone mass acquisition and turnover. <span><span class="ref-journal">Clin Endocrinol (Oxf). </span>2010;<span class="ref-vol">73</span>:707–14.</span> [<a href="/pubmed/20738314" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20738314</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.curry.1997.468">Curry CJ, Stevenson RE, Aughton D, Byrne J, Carey JC, Cassidy S, Cunniff C, Graham JM Jr, Jones MC, Kaback MM, Moeschler J, Schaefer GB, Schwartz S, Tarleton J, Opitz J. Evaluation of mental retardation: recommendations of a Consensus Conference: American College of Medical Genetics. <span><span class="ref-journal">Am J Med Genet. </span>1997;<span class="ref-vol">72</span>:468–77.</span> [<a href="/pubmed/9375733" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9375733</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.de_vries.1997.660">de Vries BB, van den Ouweland AM, Mohkamsing S, Duivenvoorden HJ, Mol E, Gelsema K, van Rijn M, Halley DJ, Sandkuijl LA, Oostra BA, Tibben A, Niermeijer MF. Screening and diagnosis for the fragile X syndrome among the mentally retarded: an epidemiological and psychological survey. Collaborative Fragile X Study Group. <span><span class="ref-journal">Am J Hum Genet. </span>1997;<span class="ref-vol">61</span>:660–7.</span> [<a href="/pmc/articles/PMC1715962/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1715962</span></a>] [<a href="/pubmed/9326332" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9326332</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.elizur.2014.e105121">Elizur SE, Lebovitz O, Derech-Haim S, Dratviman-Storobinsky O, Feldman B, Dor J, Orvieto R, Cohen Y. Elevated levels of FMR1 mRNA in granulosa cells are associated with low ovarian reserve in FMR1 premutation carriers. <span><span class="ref-journal">PLoS One. </span>2014;<span class="ref-vol">9</span>:e105121</span> [<a href="/pmc/articles/PMC4143194/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4143194</span></a>] [<a href="/pubmed/25153074" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25153074</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.erickson.2011.85">Erickson CA, Stigler KA, Wink LK, Mullett JE, Kohn A, Posey DJ, McDougle CJ. A prospective open-label study of aripiprazole in fragile X syndrome. <span><span class="ref-journal">Psychopharmacology. </span>2011;<span class="ref-vol">216</span>:85–90.</span> [<a href="/pubmed/21318565" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21318565</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.farzin.2006.s137">Farzin F, Perry H, Hessl D, Loesch D, Cohen J, Bacalman S, Gane L, Tassone F, Hagerman P, Hagerman R. Autism spectrum disorders and attention-deficit/hyperactivity disorder in boys with the fragile X premutation. <span><span class="ref-journal">J Dev Behav Pediatr. </span>2006;<span class="ref-vol">27</span>:S137–44.</span> [<a href="/pubmed/16685180" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16685180</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.fern_ndez.2015.965839">Fern&#x000e1;ndez RM, Peci&#x000f1;a A, Lozano-Arana MD, S&#x000e1;nchez B, Garc&#x000ed;a-Lozano JC, Borrego S, Anti&#x000f1;olo G. Clinical and technical overview of preimplantation genetic diagnosis for fragile X syndrome: experience at the University Hospital Virgen del Rocio in Spain. <span><span class="ref-journal">Biomed Res Int. </span>2015;2015;<span class="ref-vol">2015</span>:965839</span> [<a href="/pmc/articles/PMC4680048/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4680048</span></a>] [<a href="/pubmed/26713318" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26713318</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.fink.2018.529">Fink DA, Nelson LM, Pyeritz R, Johnson J, Sherman SL, Cohen Y, Elizur SE. Fragile X associated primary ovarian insufficiency (FXPOI): case report and literature review. <span><span class="ref-journal">Front Genet. </span>2018;<span class="ref-vol">9</span>:529.</span> [<a href="/pmc/articles/PMC6278244/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6278244</span></a>] [<a href="/pubmed/30542367" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30542367</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.finucane.2012.752_1">Finucane B, Abrams L, Cronister A, Archibald AD, Bennett RL, McConkie-Rosell A. Genetic counseling and testing for FMR1 gene mutations: practice guidelines of the national society of genetic counselors. <span><span class="ref-journal">J Genet Couns. </span>2012;<span class="ref-vol">21</span>:752–60.</span> [<a href="/pubmed/22797890" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22797890</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.finucane.2017.37">Finucane B, Lincoln S, Bailey L, Martin CL. Prognostic dilemmas and genetic counseling for prenatally detected fragile X gene expansions. <span><span class="ref-journal">Prenat Diagn. </span>2017;<span class="ref-vol">37</span>:37–42.</span> [<a href="/pubmed/27862088" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27862088</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.galloway.2009.785">Galloway JN, Nelson DL. Evidence for RNA-mediated toxicity in fragile X-associated tremor/ataxia syndrome. <span><span class="ref-journal">Future Neurol. </span>2009;<span class="ref-vol">4</span>:785.</span> [<a href="/pmc/articles/PMC2821051/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2821051</span></a>] [<a href="/pubmed/20161676" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20161676</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.gantois.2017.674">Gantois I, Khoutorsky A, Popic J, Aguilar-Valles A, Freemantle E, Cao R, Sharma V, Pooters T, Nagpal A, Skalecka A, Truong VT, Wiebe S, Groves IA, Jafarnejad SM, Chapat C, McCullagh EA, Gamache K, Nader K, Lacaille JC, Gkogkas CG, Sonenberg N. Metformin ameliorates core deficits in a mouse model of fragile X syndrome. <span><span class="ref-journal">Nat Med. </span>2017;<span class="ref-vol">23</span>:674–7.</span> [<a href="/pubmed/28504725" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28504725</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.gomezmancilla.2014.125">Gomez-Mancilla B, Berry-Kravis E, Hagerman R, von Raison F, Apostol G, Ufer M, Gasparini F, Jacquemont S. Development of mavoglurant and its potential for the treatment of fragile X syndrome. <span><span class="ref-journal">Expert Opin Investig Drugs. </span>2014 Jan;<span class="ref-vol">23</span>:125–34.</span> [<a href="/pubmed/24251408" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24251408</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.grasso.2014.23">Grasso M, Boon EM, Filipovic-Sadic S, van Bunderen PA, Gennaro E, Cao R, Latham GJ, Hadd AG, Coviello DA. A novel methylation PCR that offers standardized determination of FMR1 methylation and CGG repeat length without Southern blot analysis. <span><span class="ref-journal">J Mol Diagn. </span>2014;<span class="ref-vol">16</span>:23–31.</span> [<a href="/pmc/articles/PMC3873488/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3873488</span></a>] [<a href="/pubmed/24177047" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24177047</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.grigsby.2005">Grigsby J, Bennett R, Brega A, Bounds L, Cogswell J, Greco C, Hagerman P, Hagerman R, Hall D, Jacquemont S, Leehey M, Paulich M, Rice C, Rubinstein D, Tassone F. Fragile X-associated tremor-ataxia syndrome (FXTAS): An X-linked neurodegenerative phenotype. Abstract #280. Dallas, TX: American College of Medical Genetics Meeting; 2005.</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.guti_rrez.2013.e1">Guti&#x000e9;rrez JF, Bajaj K, Klugman SD. Prenatal screening for fragile X: carriers, controversies, and counseling. <span><span class="ref-journal">Rev Obstet Gynecol. </span>2013;<span class="ref-vol">6</span>:e1–7.</span> [<a href="/pmc/articles/PMC3651542/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3651542</span></a>] [<a href="/pubmed/23687552" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23687552</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.hadd.2016.130">Hadd AG, Filipovic-Sadic S, Zhou L, Williams A, Schlageter AM, Latham GJ, Berry-Kravis E, Hall DA. A PCR method for X-chromosome activation analysis simplifies phenotype association studies in fragile X premutation carrier women. <span><span class="ref-journal">Clin Epigenetics. </span>2016;<span class="ref-vol">8</span>:130.</span> [<a href="/pmc/articles/PMC5131543/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5131543</span></a>] [<a href="/pubmed/27980694" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27980694</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.hagerman.2011.211">Hagerman R, Au J, Hagerman P. FMR1 premutation and full mutation molecular mechanisms related to autism. <span><span class="ref-journal">J Neurodev Disord. </span>2011;<span class="ref-vol">3</span>:211–24.</span> [<a href="/pmc/articles/PMC3261276/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3261276</span></a>] [<a href="/pubmed/21617890" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21617890</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.hagerman.2009.378">Hagerman RJ, Berry-Kravis E, Kaufmann WE, Ono MY, Tartaglia N, Lachiewicz A, Kronk R, Delahunty C, Hessl D, Visootak J, Picker J, Gane L, Tranfagia M. Advances in the treatment of fragile X syndrome. <span><span class="ref-journal">Pediatrics. </span>2009;<span class="ref-vol">123</span>:378–90.</span> [<a href="/pmc/articles/PMC2888470/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2888470</span></a>] [<a href="/pubmed/19117905" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19117905</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.hagerman.2016.403">Hagerman RJ, Hagerman P. Fragile X-associated tremor/ataxia syndrome - features, mechanisms and management. <span><span class="ref-journal">Nat Rev Neurol. </span>2016;<span class="ref-vol">12</span>:403–12.</span> [<a href="/pubmed/27340021" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27340021</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.hagerman.2018.564">Hagerman RJ, Protic D, Rajaratnam A, Salcedo-Arellano MJ, Aydin EY, Schneider A. Fragile X-associated neuropsychiatric disorders (FXAND). <span><span class="ref-journal">Front Psychiatry. </span>2018;<span class="ref-vol">9</span>:564.</span> [<a href="/pmc/articles/PMC6243096/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6243096</span></a>] [<a href="/pubmed/30483160" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30483160</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.hall.2018">Hall DA, Berry-Kravis EB. Fragile X syndrome and fragile X-associated tremor ataxia syndrome. In: Geschwind DH, Paulson HL, Klein C, eds. <em>Handbook of Clinical Neurology.</em> Neurogenetics, Part I, Volume 147. Cambridge, MA: Elsevier; 2018:377-91.</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.hall.2005.299">Hall DA, Berry-Kravis E, Jacquemont S, Rice CD, Cogswell J, Zhang L, Hagerman RJ, Hagerman PJ, Leehey MA. Initial diagnoses given to persons with the fragile X associated tremor/ataxia syndrome (FXTAS). <span><span class="ref-journal">Neurology. </span>2005;<span class="ref-vol">65</span>:299–301.</span> [<a href="/pubmed/16043804" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16043804</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.hall.2016.578">Hall DA, Robertson E, Shelton AL, Losh MC, Mila M, Moreno EG, Gomez-Anson B, Mart&#x000ed;nez-Cerde&#x000f1;o V, Grigsby J, Lozano R, Hagerman R, Maria LS, Berry-Kravis E, O'Keefe JA. Update on the clinical, radiographic, and neurobehavioral manifestations in FXTAS and FMR1 premutation carriers. <span><span class="ref-journal">Cerebellum. </span>2016;<span class="ref-vol">15</span>:578–86.</span> [<a href="/pubmed/27287737" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27287737</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.han.2006.1463">Han XD, Powell BR, Phalin JL, Chehab FF. Mosaicism for a full mutation, premutation, and deletion of the CGG repeats results in 22% FMRP and elevated FMR1 mRNA levels in a high-functioning fragile X male. <span><span class="ref-journal">Am J Med Genet A. </span>2006;<span class="ref-vol">140</span>:1463–71.</span> [<a href="/pubmed/16761284" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16761284</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.hantash.2011.39">Hantash FM, Goos DM, Crossley B, Anderson B, Zhang K, Sun W, Strom CM. FMR1 premutation carrier frequency in patients undergoing routine population-based carrier screening: insights into the prevalence of fragile X syndrome, fragile X-associated tremor/ataxia syndrome, and fragile X-associated primary ovarian insufficiency in the United States. <span><span class="ref-journal">Genet Med. </span>2011;<span class="ref-vol">13</span>:39–45.</span> [<a href="/pubmed/21116185" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21116185</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.hartley.2012.53">Hartley SL, Seltzer MM, Hong J, Greenberg JS, Smith L, Almeida D, Coe C, Abbeduto L. Cortisol response to behavior problems in FMR1 premutation mothers of adolescents and adults with fragile X syndrome: a diathesis-stress model. <span><span class="ref-journal">Int J Behav Dev. </span>2012;<span class="ref-vol">36</span>:53–61.</span> [<a href="/pmc/articles/PMC3396207/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3396207</span></a>] [<a href="/pubmed/22798702" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22798702</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.hayward.2017.1313">Hayward BE, Kumari D, Usdin K. Recent advances in assays for the fragile X-related disorders. <span><span class="ref-journal">Hum Genet. </span>2017;<span class="ref-vol">136</span>:1313–27.</span> [<a href="/pmc/articles/PMC5769695/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5769695</span></a>] [<a href="/pubmed/28866801" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28866801</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.hayward.2016.762">Hayward BE, Zhou Y, Kumari D, Usdin K. A set of assays for the comprehensive analysis of FMR1 alleles in the fragile X-related disorders. <span><span class="ref-journal">J Mol Diagn. </span>2016;<span class="ref-vol">18</span>:762–74.</span> [<a href="/pmc/articles/PMC5807930/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5807930</span></a>] [<a href="/pubmed/27528259" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27528259</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.hessl.2011.859">Hessl D, Wang JM, Schneider A, Koldewyn K, Le L, Iwahashi C, Cheung K, Tassone F, Hagerman PJ, Rivera SM. Decreased fragile X mental retardation protein expression underlies amygdala dysfunction in carriers of the fragile X premutation. <span><span class="ref-journal">Biol Psychiatry. </span>2011;<span class="ref-vol">70</span>:859–65.</span> [<a href="/pmc/articles/PMC3191264/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3191264</span></a>] [<a href="/pubmed/21783174" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21783174</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.hipp.2016.993">Hipp HS, Charen KH, Spencer JB, Allen EG, Sherman SL. Reproductive and gynecologic care of women with fragile X primary ovarian insufficiency (FXPOI). <span><span class="ref-journal">Menopause. </span>2016;<span class="ref-vol">23</span>:993–9.</span> [<a href="/pmc/articles/PMC4998843/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4998843</span></a>] [<a href="/pubmed/27552334" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27552334</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.hunter.2009.79">Hunter JE, Abramowitz A, Rusin M, Sherman SL. Is there evidence for neuropsychological and neurobehavioral phenotypes among adults without FXTAS who carry FMR1 premutation? A review of current literature. <span><span class="ref-journal">Genet Med. </span>2009;<span class="ref-vol">11</span>:79–89.</span> [<a href="/pmc/articles/PMC2652667/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2652667</span></a>] [<a href="/pubmed/19265746" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19265746</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.hunter.2014.1648">Hunter J, Rivero-Arias O, Angelov A, Kim E, Fotheringham I, Leal J. Epidemiology of fragile X syndrome: a systematic review and meta-analysis. <span><span class="ref-journal">Am J Med Genet A. </span>2014;<span class="ref-vol">164A</span>:1648–58.</span> [<a href="/pubmed/24700618" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24700618</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.ishiura.2019.1222">Ishiura H, Shibata S, Yoshimura J, Suzuki Y, Qu W, Doi K, Almansour MA, Kikuchi JK, Taira M, Mitsui J, Takahashi Y, Ichikawa Y, Mano T, Iwata A, Harigaya Y, Matsukawa MK, Matsukawa T, Tanaka M, Shirota Y, Ohtomo R, Kowa H, Date H, Mitsue A, Hatsuta H, Morimoto S, Murayama S, Shiio Y, Saito Y, Mitsutake A, Kawai M, Sasaki T, Sugiyama Y, Hamada M, Ohtomo G, Terao Y, Nakazato Y, Takeda A, Sakiyama Y, Umeda-Kameyama Y, Shinmi J, Ogata K, Kohno Y, Lim SY, Tan AH, Shimizu J, Goto J, Nishino I, Toda T, Morishita S, Tsuji S. Noncoding CGG repeat expansions in neuronal intranuclear inclusion disease, oculopharyngodistal myopathy and an overlapping disease. <span><span class="ref-journal">Nat Genet. </span>2019;<span class="ref-vol">51</span>:1222–32.</span> [<a href="/pubmed/31332380" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31332380</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.jacquemont.2003.869">Jacquemont S, Hagerman RJ, Leehey M, Grigsby J, Zhang L, Brunberg JA, Greco C, Des Portes V, Jardini T, Levine R, Berry-Kravis E, Brown WT, Schaeffer S, Kissel J, Tassone F, Hagerman PJ. Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates. <span><span class="ref-journal">Am J Hum Genet. </span>2003;<span class="ref-vol">72</span>:869–78.</span> [<a href="/pmc/articles/PMC1180350/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1180350</span></a>] [<a href="/pubmed/12638084" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12638084</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.jeve.2016.1471">Jeve YB, Potdar N, Opoku A, Khare M. Donor oocyte conception and pregnancy complications: a systematic review and meta-analysis. <span><span class="ref-journal">BJOG. </span>2016;<span class="ref-vol">123</span>:1471–80.</span> [<a href="/pubmed/26854328" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26854328</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.kaufmann.2017.s194">Kaufmann WE, Kidd SA, Andrews HF, Budimirovic DB, Esler A, Haas-Givler B, Stackhouse T, Peacock G, Riley C, Sherman SL, Brown WT, Berry-Kravis E. Autism spectrum disorder in fragile X syndrome: characterization using FORWARD. <span><span class="ref-journal">Pediatrics. </span>2017;<span class="ref-vol">139</span>:S194–206.</span> [<a href="/pmc/articles/PMC5619699/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5619699</span></a>] [<a href="/pubmed/28814540" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28814540</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.kidd.2019">Kidd SA, Berry-Kravis E, Choo TH, Chen C, Esler A, Hoffmann A, Andrews HF, Kaufmann WE. Improving the diagnosis of autism spectrum disorder in fragile X syndrome by adapting the Social Communication Questionnaire and the Social Responsiveness Scale-2. <span><span class="ref-journal">J Autism Dev Disord. </span>2019.</span> Epub ahead of print. [<a href="/pubmed/31342442" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31342442</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.kidd.2014.995">Kidd SA, Lachiewicz A, Barbouth D, Blitz RK, Delahunty C, McBrien D, Visootsak J, Berry-Kravis E. Fragile X syndrome: a review of associated medical problems. <span><span class="ref-journal">Pediatrics. </span>2014;<span class="ref-vol">134</span>:995–1005.</span> [<a href="/pubmed/25287458" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25287458</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.lawrenz.2019.998">Lawrenz B, El Khatib I, Li&#x000f1;&#x000e1;n A, Bayram A, Arnanz A, Chopra R, De Munck N, Fatemi HM. The clinicians' dilemma with mosaicism-an insight from inner cell mass biopsies. <span><span class="ref-journal">Hum Reprod. </span>2019;<span class="ref-vol">34</span>:998–1010.</span> [<a href="/pubmed/31114858" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31114858</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.leehey.2008.1397">Leehey MA, Berry-Kravis E, Goetz CG, Zhang L, Hall DA, Li L, Rice CD, Lara R, Cogswell J, Reynolds A, Gane L, Jacquemont S, Tassone F, Grigsby J, Hagerman RJ, Hagerman PJ. FMR1 CGG repeat length predicts motor dysfunction in premutation carriers. <span><span class="ref-journal">Neurology. </span>2008;<span class="ref-vol">70</span>:1397–402.</span> [<a href="/pmc/articles/PMC2685188/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2685188</span></a>] [<a href="/pubmed/18057320" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18057320</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.lekovich.2018.957">Lekovich J, Man L, Xu K, Canon C, Lilienthal D, Stewart JD, Pereira N, Rosenwaks Z, Gerhardt J. CGG repeat length and AGG interruptions as indicators of fragile X-associated diminished ovarian reserve. <span><span class="ref-journal">Genet Med. </span>2018;<span class="ref-vol">20</span>:957–64.</span> [<a href="/pubmed/29267266" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29267266</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.loat.2006.555">Loat CS, Craig G, Plomin R, Craig IW. Investigating the relationship between FMR1 allele length and cognitive ability in children: a subtle effect of the normal allele range on the normal ability range? <span><span class="ref-journal">Ann Hum Genet. </span>2006;<span class="ref-vol">70</span>:555–65.</span> [<a href="/pubmed/16907702" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16907702</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.loesch.2015.173">Loesch DZ, Bui MQ, Hammersley E, Schneider A, Storey E, Stimpson P, Burgess T, Francis D, Slater H, Tassone F, Hagerman RJ, Hessl D. Psychological status in female carriers of premutation FMR1 allele showing a complex relationship with the size of CGG expansion. <span><span class="ref-journal">Clin Genet. </span>2015;<span class="ref-vol">87</span>:173–8.</span> [<a href="/pmc/articles/PMC4115039/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4115039</span></a>] [<a href="/pubmed/24428240" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24428240</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.mackenzie.2006.39">MacKenzie JJ, Sumargo I, Taylor SA. A cryptic full mutation in a male with a classical fragile X phenotype. <span><span class="ref-journal">Clin Genet. </span>2006;<span class="ref-vol">70</span>:39–42.</span> [<a href="/pubmed/16813602" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16813602</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.maenner.2013.466">Maenner MJ, Baker MW, Broman KW, Tian J, Barnes JK, Atkins A, McPherson E, Hong J, Brilliant MH, Mailick MR. FMR1 CGG expansions: prevalence and sex ratios. <span><span class="ref-journal">Am J Med Genet B Neuropsychiatr Genet. </span>2013;<span class="ref-vol">162B</span>:466–73.</span> [<a href="/pmc/articles/PMC3885228/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3885228</span></a>] [<a href="/pubmed/23740716" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23740716</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.manning.2010.742">Manning M, Hudgins L. Array-based technology and recommendations for utilization in medical genetics practice for detection of chromosomal abnormalities. <span><span class="ref-journal">Genet Med. </span>2010;<span class="ref-vol">12</span>:742–5.</span> [<a href="/pmc/articles/PMC3111046/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3111046</span></a>] [<a href="/pubmed/20962661" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20962661</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.miller.2010.749">Miller DT, Adam MP, Aradhya S, Biesecker LG, Brothman AR, Carter NP, Church DM, Crolla JA, Eichler EE, Epstein CJ, Faucett WA, Feuk L, Friedman JM, Hamosh A, Jackson L, Kaminsky EB, Kok K, Krantz ID, Kuhn RM, Lee C, Ostell JM, Rosenberg C, Scherer SW, Spinner NB, Stavropoulos DJ, Tepperberg JH, Thorland EC, Vermeesch JR, Waggoner DJ, Watson MS, Martin CL, Ledbetter DH. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. <span><span class="ref-journal">Am J Hum Genet. </span>2010;<span class="ref-vol">86</span>:749–64.</span> [<a href="/pmc/articles/PMC2869000/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2869000</span></a>] [<a href="/pubmed/20466091" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20466091</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.monyak.2017.1140">Monyak RE, Emerson D, Schoenfeld BP, Zheng X, Chambers DB, Rosenfelt C, Langer S, Hinchey P, Choi CH, McDonald TV, Bolduc FV, Sehgal A, McBride SMJ, Jongens TA. Insulin signaling misregulation underlies circadian and cognitive deficits in a Drosophila fragile X model. <span><span class="ref-journal">Mol Psychiatry. </span>2017;<span class="ref-vol">22</span>:1140–8.</span> [<a href="/pmc/articles/PMC5071102/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5071102</span></a>] [<a href="/pubmed/27090306" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27090306</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.nahhas.2012.187">Nahhas FA, Monroe TJ, Prior TW, Botma PI, Fang J, Snyder PJ, Talbott SL, Feldman GL. Evaluation of the human fragile X mental retardation 1 polymerase chain reaction reagents to amplify the FMR1 gene: testing in a clinical diagnostic laboratory. <span><span class="ref-journal">Genet Test Mol Biomarkers. </span>2012;<span class="ref-vol">16</span>:187–92.</span> [<a href="/pubmed/21992462" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21992462</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.napoli.2019.3702">Napoli E, Schneider A, Wang JY, Trivedi A, Carrillo NR, Tassone F, Rogawski M, Hagerman RJ, Giulivi C. Allopregnanolone treatment improves plasma metabolomic profile associated with GABA metabolism in fragile X-associated tremor/ataxia syndrome: a pilot study. <span><span class="ref-journal">Mol Neurobiol. </span>2019;<span class="ref-vol">56</span>:3702–13.</span> [<a href="/pmc/articles/PMC6401336/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6401336</span></a>] [<a href="/pubmed/30187385" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30187385</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.nayot.2013.1439">Nayot D, Chung JT, Son WY, Ao A, Hughes M, Dahan MH. Live birth following serial vitrification of embryos and PGD for fragile X syndrome in a patient with the premutation and decreased ovarian reserve. <span><span class="ref-journal">J Assist Reprod Genet. </span>2013;<span class="ref-vol">30</span>:1439–44.</span> [<a href="/pmc/articles/PMC3879937/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3879937</span></a>] [<a href="/pubmed/24062195" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24062195</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.nelson.2009.606">Nelson LM. Primary ovarian insufficiency. <span><span class="ref-journal">NEJM. </span>2009;<span class="ref-vol">360</span>:606–14.</span> [<a href="/pmc/articles/PMC2762081/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2762081</span></a>] [<a href="/pubmed/19196677" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19196677</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.nelson.2005.1327">Nelson LM, Covington SN, Rebar RW. An update: spontaneous premature ovarian failure is not an early menopause. <span><span class="ref-journal">Fertil Steril. </span>2005;<span class="ref-vol">83</span>:1327–32.</span> [<a href="/pubmed/15866564" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15866564</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.nolin.2011.925">Nolin SL, Glicksman A, Ding X, Ersalesi N, Brown WT, Sherman SL, Dobkin C. Fragile X analysis of 1112 prenatal samples from 1991 to 2010. <span><span class="ref-journal">Prenat Diagn. </span>2011;<span class="ref-vol">31</span>:925–31.</span> [<a href="/pubmed/21717484" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21717484</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.nolin.2015.358">Nolin SL, Glicksman A, Ersalesi N, Dobkin C, Brown WT, Cao R, Blatt E, Sah S, Latham GJ, Hadd AG. Fragile X full mutation expansions are inhibited by one or more AGG interruptions in premutation carriers. <span><span class="ref-journal">Genet Med. </span>2015;<span class="ref-vol">17</span>:358–64.</span> [<a href="/pubmed/25210937" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25210937</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.nolin.2019.1148">Nolin SL, Glicksman A, Tortora N, Allen E, Macpherson J, Mila M, Vianna-Morgante AM, Sherman SL, Dobkin C, Latham GJ, Hadd AG. Expansions and contractions of the FMR1 CGG repeat in 5,508 transmissions of normal, intermediate, and premutation alleles. <span><span class="ref-journal">Am J Med Genet A. </span>2019;<span class="ref-vol">179</span>:1148–56.</span> [<a href="/pmc/articles/PMC6619443/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6619443</span></a>] [<a href="/pubmed/31050164" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31050164</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.nolin.2013.771">Nolin SL, Sah S, Glicksman A, Sherman SL, Allen E, Berry-Kravis E, Tassone F, Yrigollen C, Cronister A, Jodah M, Ersalesi N, Dobkin C, Brown WT, Shroff R, Latham GJ, Hadd AG. Fragile X AGG analysis provides new risk predictions for 45&#x02013;69 repeat alleles. <span><span class="ref-journal">Am J Med Genet Part A. </span>2013;<span class="ref-vol">161A</span>:771–8.</span> [<a href="/pmc/articles/PMC4396070/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4396070</span></a>] [<a href="/pubmed/23444167" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23444167</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.north_american_menopause_society.2012.257">North American Menopause Society.  The 2012 hormone therapy position statement of: The North American Menopause Society. <span><span class="ref-journal">Menopause. </span>2012;<span class="ref-vol">19</span>:257–71.</span> [<a href="/pmc/articles/PMC3443956/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3443956</span></a>] [<a href="/pubmed/22367731" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22367731</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.orpana.2012.2081">Orpana AK, Ho TH, Stenman J. Multiple heat pulses during PCR extension enabling amplification of GC-rich sequences and reducing amplification bias. <span><span class="ref-journal">Anal Chem. </span>2012;<span class="ref-vol">84</span>:2081–7.</span> [<a href="/pubmed/22220596" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22220596</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.rajanbabu.2017.e10">Rajan-Babu IS, Lian M, Cheah FSH, Chen M, Tan ASC, Prasath EB, Loh SF, Chong SS. FMR1 CGG repeat expansion mutation detection and linked haplotype analysis for reliable and accurate preimplantation genetic diagnosis of fragile X syndrome. <span><span class="ref-journal">Expert Rev Mol Med. </span>2017;<span class="ref-vol">19</span>:e10</span> [<a href="/pmc/articles/PMC5733830/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5733830</span></a>] [<a href="/pubmed/28720156" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28720156</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.rauch.2006.2063">Rauch A, Hoyer J, Guth S, Zweier C, Kraus C, Becker C, Zenker M, H&#x000fc;ffmeier U, Thiel C, R&#x000fc;schendorf F, N&#x000fc;rnberg P, Reis A, Trautmann U. Diagnostic yield of various genetic approaches in patients with unexplained developmental delay or mental retardation. <span><span class="ref-journal">Am J Med Genet A. </span>2006;<span class="ref-vol">140</span>:2063–74.</span> [<a href="/pubmed/16917849" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16917849</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.renda.2014.326">Renda MM, Voigt RG, Babovic-Vuksanovic D, Highsmith WE, Vinson SS, Sadowski CM, Hagerman RJ. Neurodevelopmental disabilities in children with intermediate and premutation range fragile X cytosineguanine- guanine expansions. <span><span class="ref-journal">J Child Neurol. </span>2014;<span class="ref-vol">29</span>:326–30.</span> [<a href="/pubmed/23266944" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23266944</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.riddle.1998.590">Riddle JE, Cheema A, Sobesky WE, Gardner SC, Taylor AK, Pennington BF, Hagerman RJ. Phenotypic involvement in females with the FMR1 gene mutation. <span><span class="ref-journal">Am J Ment Retard. </span>1998;<span class="ref-vol">102</span>:590–601.</span> [<a href="/pubmed/9606468" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9606468</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.rodriguezrevenga.2009.1359">Rodriguez-Revenga L, Madrigal I, Pagonabarraga J, Xuncl&#x000e0; M, Badenas C, Kulisevsky J, Gomez B, Mil&#x000e0; M. Penetrance of FMR1 premutation associated pathologies in fragile X syndrome families. <span><span class="ref-journal">Eur J Hum Genet. </span>2009;<span class="ref-vol">17</span>:1359–62.</span> [<a href="/pmc/articles/PMC2986640/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2986640</span></a>] [<a href="/pubmed/19367323" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19367323</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.sansone.2014.16">Sansone SM, Schneider A, Bickel E, Berry-Kravis E, Prescott C, Hessl D. Improving IQ measurement in intellectual disabilities using true deviation from population norms. <span><span class="ref-journal">J Neurodev Disord. </span>2014;<span class="ref-vol">6</span>:16.</span> [<a href="/pmc/articles/PMC4613563/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4613563</span></a>] [<a href="/pubmed/26491488" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26491488</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.santoro.2012.219">Santoro MR, Bray SM, Warren ST. Molecular mechanisms of fragile X syndrome: a twenty-year perspective. <span><span class="ref-journal">Annu Rev Pathol. </span>2012;<span class="ref-vol">7</span>:219–45.</span> [<a href="/pubmed/22017584" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22017584</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.schufreider.2015.2686">Schufreider A, McQueen DB, Lee SM, Allon R, Uhler ML, Davie J, Feinberg EC. Diminished ovarian reserve is not observed in infertility patients with high normal CGG repeats on the fragile X mental retardation 1 (FMR1) gene. <span><span class="ref-journal">Hum Reprod. </span>2015;<span class="ref-vol">30</span>:2686–92.</span> [<a href="/pubmed/26345686" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26345686</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.seltzer.2012.612">Seltzer MM, Barker ET, Greenberg JS, Hong J, Coe C, Almeida D. Differential sensitivity to life stress in FMR1 premutation carrier mothers of children with fragile X syndrome. <span><span class="ref-journal">Health Psychol. </span>2012;<span class="ref-vol">31</span>:612–22.</span> [<a href="/pmc/articles/PMC3434309/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3434309</span></a>] [<a href="/pubmed/22149120" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22149120</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.seritan.2013.59">Seritan AL, Ortigas M, Seritan S, Bourgeois JA, Hagerman RJ. Psychiatric disorders associated with FXTAS. <span><span class="ref-journal">Curr Psychiatry Rev. </span>2013;<span class="ref-vol">9</span>:59–64.</span> [<a href="/pmc/articles/PMC4304643/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4304643</span></a>] [<a href="/pubmed/25620899" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25620899</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.sherman.2005">Sherman S. Clinical implications of gray-zone FMR1 alleles. Abstract #308. Dallas, TX: American College of Medical Genetics Meeting; 2005.</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.sherman.2005.584_1">Sherman S, Pletcher BA, Driscoll DA. Fragile X syndrome: diagnostic and carrier testing. <span><span class="ref-journal">Genet Med. </span>2005;<span class="ref-vol">7</span>:584–7.</span> [<a href="/pmc/articles/PMC3110946/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3110946</span></a>] [<a href="/pubmed/16247297" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16247297</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.sherman.2000.189_1">Sherman SL. Premature ovarian failure in the fragile X syndrome. <span><span class="ref-journal">Am J Med Genet. </span>2000;<span class="ref-vol">97</span>:189–94.</span> [<a href="/pubmed/11449487" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11449487</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.shevell.2003.367">Shevell M, Ashwal S, Donley D, Flint J, Gingold M, Hirtz D, Majnemer A, Noetzel M, Sheth RD. Practice parameter: evaluation of the child with global developmental delay: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. <span><span class="ref-journal">Neurology. </span>2003;<span class="ref-vol">60</span>:367–80.</span> [<a href="/pubmed/12578916" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12578916</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.sitzmann.2018.11">Sitzmann AF, Hagelstrom RT, Tassone F, Hagerman RJ, Butler MG. Rare FMR1 gene mutations causing fragile X syndrome: a review. <span><span class="ref-journal">Am J Med Genet. </span>2018;<span class="ref-vol">176</span>:11–8.</span> [<a href="/pmc/articles/PMC6697153/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6697153</span></a>] [<a href="/pubmed/29178241" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29178241</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.sone.2019.1215">Sone J, Mitsuhashi S, Fujita A, Mizuguchi T, Hamanaka K, Mori K, Koike H, Hashiguchi A, Takashima H, Sugiyama H, Kohno Y, Takiyama Y, Maeda K, Doi H, Koyano S, Takeuchi H, Kawamoto M, Kohara N, Ando T, Ieda T, Kita Y, Kokubun N, Tsuboi Y, Katoh K, Kino Y, Katsuno M, Iwasaki Y, Yoshida M, Tanaka F, Suzuki IK, Frith MC, Matsumoto N, Sobue G. Long-read sequencing identifies GGC repeat expansions in NOTCH2NLC associated with neuronal intranuclear inclusion disease. <span><span class="ref-journal">Nat Genet. </span>2019;<span class="ref-vol">51</span>:1215–21.</span> [<a href="/pubmed/31332381" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31332381</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.sone.2016.3170">Sone J, Mori K, Inagaki T, Katsumata R, Takagi S, Yokoi S, Araki K, Kato T, Nakamura T, Koike H, Takashima H, Hashiguchi A, Kohno Y, Kurashige T, Kuriyama M, Takiyama Y, Tsuchiya M, Kitagawa N, Kawamoto M, Yoshimura H, Suto Y, Nakayasu H, Uehara N, Sugiyama H, Takahashi M, Kokubun N, Konno T, Katsuno M, Tanaka F, Iwasaki Y, Yoshida M, Sobue G. Clinicopathological features of adult-onset neuronal intranuclear inclusion disease. <span><span class="ref-journal">Brain. </span>2016;<span class="ref-vol">139</span>:3170–86.</span> [<a href="/pmc/articles/PMC5382941/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5382941</span></a>] [<a href="/pubmed/27797808" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27797808</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.tartagni.2007.858">Tartagni M, Cicinelli E, De Pergola G, De Salvia MA, Lavopa C, Loverro G. Effects of pretreatment with estrogens on ovarian stimulation with gonadotropins in women with premature ovarian failure: a randomized, placebo-controlled trial. <span><span class="ref-journal">Fertil Steril. </span>2007;<span class="ref-vol">87</span>:858–61.</span> [<a href="/pubmed/17261285" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17261285</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.tassone.2007.566">Tassone F, Adams J, Berry-Kravis EM, Cohen SS, Brusco A, Leehey MA, Li L, Hagerman RJ, Hagerman PJ. CGG repeat length correlates with age of onset of motor signs of the fragile X-associated tremor/ataxia syndrome (FXTAS). <span><span class="ref-journal">Am J Med Genet B Neuropsychiatr Genet. </span>2007;<span class="ref-vol">144B</span>:566–9.</span> [<a href="/pubmed/17427188" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17427188</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.tassone.1999.250">Tassone F, Hagerman RJ, Ikle DN, Dyer PN, Lampe M, Willemsen R, Oostra BA, Taylor AK. FMRP expression as a potential prognostic indicator in fragile X syndrome. <span><span class="ref-journal">Am J Med Genet. </span>1999;<span class="ref-vol">84</span>:250–61.</span> [<a href="/pubmed/10331602" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10331602</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.tassone.2012.100">Tassone F, Iong KP, Tong TH, Lo J, Gane LW, Berry-Kravis E, Nguyen D, Mu LY, Laffin J, Bailey DB, Hagerman RJ. FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States. <span><span class="ref-journal">Genome Med. </span>2012;<span class="ref-vol">4</span>:100.</span> [<a href="/pmc/articles/PMC4064316/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4064316</span></a>] [<a href="/pubmed/23259642" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23259642</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.tian.2019.166">Tian Y, Wang JL, Huang W, Zeng S, Jiao B, Liu Z, Chen Z, Li Y, Wang Y, Min HX, Wang XJ, You Y, Zhang RX, Chen XY, Yi F, Zhou YF, Long HY, Zhou CJ, Hou X, Wang JP, Xie B, Liang F, Yang ZY, Sun QY, Allen EG, Shafik AM, Kong HE, Guo JF, Yan XX, Hu ZM, Xia K, Jiang H, Xu HW, Duan RH, Jin P, Tang BS, Shen L. Expansion of human-specific GGC repeat in neuronal intranuclear inclusion disease-related disorders. <span><span class="ref-journal">Am J Hum Genet. </span>2019;<span class="ref-vol">105</span>:166–76.</span> [<a href="/pmc/articles/PMC6612530/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6612530</span></a>] [<a href="/pubmed/31178126" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31178126</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.voorhuis.2014.1585">Voorhuis M, Onland-Moret NC, Janse F, Ploos van Amstel HK, Goverde AJ, Lambalk CB, Laven JS, van der Schouw YT, Broekmans FJ, Fauser BC, et al.  The significance of fragile X mental retardation gene 1 CGG repeat sizes in the normal and intermediate range in women with primary ovarian insufficiency. <span><span class="ref-journal">Hum Reprod. </span>2014;<span class="ref-vol">29</span>:1585–93.</span> [<a href="/pubmed/24812319" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24812319</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.wang.2017.1073">Wang JY, Trivedi AM, Carrillo NR, Yang J, Schneider A, Giulivi C, Adams P, Tassone F, Kim K, Rivera SM, Lubarr N, Wu CY, Irwin RW, Brinton RD, Olichney JM, Rogawski MA, Hagerman RJ. Open-label allopregnanolone treatment of men with fragile X-associated tremor/ataxia syndrome. <span><span class="ref-journal">Neurotherapeutics. </span>2017;<span class="ref-vol">14</span>:1073–83.</span> [<a href="/pmc/articles/PMC5722761/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5722761</span></a>] [<a href="/pubmed/28707277" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28707277</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.weber.2019.e18">Weber JD, Smith E, Berry-Kravis E, Cadavid D, Hessl D, Erickson C. Voice of people with fragile X syndrome and their families: reports from a survey on treatment priorities. <span><span class="ref-journal">Brain Sci. </span>2019;<span class="ref-vol">9</span>:E18</span> pii. [<a href="/pmc/articles/PMC6406416/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6406416</span></a>] [<a href="/pubmed/30678024" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30678024</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.wheeler.2017.s172">Wheeler A, Raspa M, Hagerman R, Mailick M, Riley C. Implications of the FMR1 premutation for children, adolescents, adults, and their families. <span><span class="ref-journal">Pediatrics. </span>2017;<span class="ref-vol">139</span>:S172–82.</span> [<a href="/pmc/articles/PMC5621635/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5621635</span></a>] [<a href="/pubmed/28814538" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28814538</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.wheeler.2014.30">Wheeler AC, Bailey DB Jr, Berry-Kravis E, Greenberg J, Losh M, Mailick M, Mil&#x000e0; M, Olichney JM, Rodriguez-Revenga L, Sherman S, Smith L, Summers S, Yang JC, Hagerman R. Associated features in females with an FMR1 premutation. <span><span class="ref-journal">J Neurodev Disord. </span>2014;<span class="ref-vol">6</span>:30.</span> [<a href="/pmc/articles/PMC4121434/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4121434</span></a>] [<a href="/pubmed/25097672" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25097672</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.wirojanan.2008.888">Wirojanan J, Angkustsiri K, Tassone F, Gane LW, Hagerman RJ. A girl with fragile X premutation from sperm donation. <span><span class="ref-journal">Am J Med Genet A. </span>2008;<span class="ref-vol">146A</span>:888–92.</span> [<a href="/pubmed/18286596" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18286596</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.yrigollen.2012.729">Yrigollen CM, Durbin-Johnson B, Gane L, Nelson DL, Hagerman R, Hagerman PJ, Tassone F. AGG interruptions within the maternal FMR1 gene reduce the risk of offspring with fragile X syndrome. <span><span class="ref-journal">Genet Med. </span>2012;<span class="ref-vol">14</span>:729–36.</span> [<a href="/pmc/articles/PMC3990283/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3990283</span></a>] [<a href="/pubmed/22498846" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22498846</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fragilex.REF.yrigollen.2014.153">Yrigollen CM, Sweha S, Durbin-Johnson B, Zhou L, Berry-Kravis E, Fernandez-Carvajal I, Faradz SM, Amiri K, Shaheen H, Polli R, Murillo-Bonilla L, Silva Arevalo Gde J, Cogram P, Murgia A, Tassone F. Distribution of AGG interruption patterns within nine world populations. <span><span class="ref-journal">Intractable Rare Dis Res. </span>2014;<span class="ref-vol">3</span>:153–61.</span> [<a href="/pmc/articles/PMC4298645/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4298645</span></a>] [<a href="/pubmed/25606365" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25606365</span></a>]</div></li></ul></div></div><div id="fragilex.Chapter_Notes"><h2 id="_fragilex_Chapter_Notes_">Chapter Notes</h2><div id="fragilex.Author_History"><h3>Author History</h3><p>Elizabeth Berry-Kravis, MD, PhD (2019-present)<br />Heather Hipp, MD (2019-present)<br />Jessica Ezzell Hunter, PhD (2019-present)<br />Robert A Saul, MD, FACMG; Greenwood Genetics Center (1998-2019)<br />Jack C Tarleton, PhD, FACMG; Fullerton Genetics Center, Asheville (1998-2019)<br />Peter K Todd, MD, PhD (2019-present)</p></div><div id="fragilex.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>21 November 2019 (ha) Comprehensive update posted live</div></li><li class="half_rhythm"><div>26 April 2012 (rs/jt) Revision: clarification in Clinical Diagnosis and Natural History sections</div></li><li class="half_rhythm"><div>26 January 2012 (cd) Revision: AGG <a class="def" href="/books/n/gene/glossary/def-item/genotyping/">genotyping</a> as a discrete test to determine number and location of AGG interruptions with CGG repeats in <i>FMR1</i> listed in GeneTests&#x02122; Laboratory Directory; findings re POI reported in 16 June 2011 revision confirmed; new data on risk for intermediate and <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> expansion when a family history of fragile X syndrome is present</div></li><li class="half_rhythm"><div>16 June 2011 (cd) Revision: repeats in the high-normal range found not to predispose to POI [<a class="bk_pop" href="#fragilex.REF.bennett.2010.1335">Bennett et al 2010</a>]</div></li><li class="half_rhythm"><div>28 October 2010 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>5 August 2008 (cd) Revision: <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>/<a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> testing available clinically</div></li><li class="half_rhythm"><div>7 March 2008 (cd) Revision: <a class="def" href="/books/n/gene/glossary/def-item/fish/">FISH</a> analysis available clinically</div></li><li class="half_rhythm"><div>20 December 2007 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>15 March 2007 (cd) Revision: correction of the wording and the discrepancy associated with only using <a class="def" href="/books/n/gene/glossary/def-item/premutation/">premutation</a> when gray zone (AKA intermediate) <i>FMR1</i> alleles also present increased risk</div></li><li class="half_rhythm"><div>25 April 2006 (bp) Revision: <a class="figpopup" href="/books/NBK1384/table/fragilex.T.odds_ratios_for_fxpoi_by_prem/?report=objectonly" target="object" rid-figpopup="figfragilexToddsratiosforfxpoibyprem" rid-ob="figobfragilexToddsratiosforfxpoibyprem">Table 4</a> updated according to Nolin et al (2003)</div></li><li class="half_rhythm"><div>1 March 2006 (cd) Revision: updated ACMG practice guideline</div></li><li class="half_rhythm"><div>2 December 2005 (jt) Revision: <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of <i>FMR1</i> clinically available; updated <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> recommendations</div></li><li class="half_rhythm"><div>24 May 2005 (rs/jt) Comprehensive update: change in scope of <i>GeneReview</i> from fragile X syndrome to <i>FMR1</i>-related disorders</div></li><li class="half_rhythm"><div>13 September 2004 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>20 April 2004 (jt) Revisions: Testing Algorithm; FXTAS</div></li><li class="half_rhythm"><div>22 November 2002 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>26 May 2000 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>16 June 1998 (pb) Review posted live</div></li><li class="half_rhythm"><div>May 1996 (jt) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1384</span><span class="label">PMID: <a href="/pubmed/20301558" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301558</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/flnb-dis/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/foxp2-sl-dis/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1384&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1384/?report=reader">PubReader</a></li><li><a href="/books/NBK1384/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1384" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1384" style="display:none" title="Cite this Page"><div class="bk_tt">Hunter JE, Berry-Kravis E, Hipp H, et al. FMR1 Disorders. 1998 Jun 16 [Updated 2019 Nov 21]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1384/pdf/Bookshelf_NBK1384.pdf">PDF version of this page</a> (655K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#fragilex.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#fragilex.GeneReview_Scope" ref="log$=inpage&amp;link_id=inpage"><i>GeneReview</i> Scope</a></li><li><a href="#fragilex.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#fragilex.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#fragilex.Genetically_Related_Allelic_Dis" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#fragilex.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#fragilex.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#fragilex.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#fragilex.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#fragilex.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#fragilex.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#fragilex.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=2332[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">FMR1</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1476276" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1476276" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1476276" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1476276" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23560306" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Unstable mutations in the FMR1 gene and the phenotypes.</a><span class="source">[Adv Exp Med Biol. 2012]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Unstable mutations in the FMR1 gene and the phenotypes.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Loesch D, Hagerman R. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Adv Exp Med Biol. 2012; 769:78-114. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/25920745" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">High functioning male with fragile X syndrome and fragile X-associated tremor/ataxia syndrome.</a><span class="source">[Am J Med Genet A. 2015]</span><div class="brieflinkpop offscreen_noflow">High functioning male with fragile X syndrome and fragile X-associated tremor/ataxia syndrome.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Basuta K, Schneider A, Gane L, Polussa J, Woodruff B, Pretto D, Hagerman R, Tassone F. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Am J Med Genet A. 2015 Sep; 167A(9):2154-61. Epub 2015 Apr 29.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/25606363" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Fragile X spectrum disorders.</a><span class="source">[Intractable Rare Dis Res. 2014]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Fragile X spectrum disorders.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lozano R, Rosero CA, Hagerman RJ. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Intractable Rare Dis Res. 2014 Nov; 3(4):134-46. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/29325626" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Fragile X syndrome and fragile X-associated tremor ataxia syndrome.</a><span class="source">[Handb Clin Neurol. 2018]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Fragile X syndrome and fragile X-associated tremor ataxia syndrome.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Hall DA, Berry-Kravis E. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Handb Clin Neurol. 2018; 147:377-391. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/29688643" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> [FMR1 PREMUTATION CARRIERS - ARE THEY REALLY ASYMPTOMATIC?]</a><span class="source">[Harefuah. 2018]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> [FMR1 PREMUTATION CARRIERS - ARE THEY REALLY ASYMPTOMATIC?]<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Elizur S, Berkenstadt M, Ries-Levavi L, Gruber N, Pinhas-Hamiel O, Hassin-Baer S, Raas-Rothschild A, Raanani H, Cukierman-Yaffe T, Orvieto R, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Harefuah. 2018 Apr; 157(4):241-244. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301558" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301558" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e041557dde0891169fed31d">FMR1 Disorders - GeneReviews®</a><div class="ralinkpop offscreen_noflow">FMR1 Disorders - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:05:11-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal102&amp;ncbi_phid=CE890093E04063E10000000007600325&amp;ncbi_session=CE890093E0415561_1888SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1384%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1384&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1384/&amp;ncbi_pagename=FMR1 Disorders - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE890093E0415561_1888SID /projects/books/PBooks@5.22 portal102 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>